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Joseph F. Costello
Loyola University Chicago
THE ROLE OF METHYLATION AND CHROMATIN STRUCTURE IN THE
REGULATION OF THE 06-METHYLGUANINE DNA
METHYLTRANSFERASE GENE IN HUMAN GLIOMA CELLS

There is considerable interest in identifying factors responsible for expression
of the 0-6-methylguanine DNA methyltransferase (MGMT) gene as MGMT is a
major determinant in the response of glioma cells to the chemotherapeutic agent 1,3
bis(2-chloroethyl)-1-nitrosourea (BCNU). Since the majority of glioma cells express
the MGMT gene, understanding factors that regulate MGMT expression is critical
for the design of therapeutic strategies to inhibit MGMT expression and thereby
overcome BCNU resistance. MGMT expression is presumed, but not proven to be
regulated at the transcriptional level. Consistent with a transcriptional level of
regulation, preliminary studies suggested that cytosine methylation may be one
factor that influences MGMT expression. This dissertation was therefore designed
to address the role of cytosine methylation in MGMT gene expression in human
glioma cells.
In order to develop the probes for examining methylation within the MGMT
gene, a map of the coding sequences of the MGMT gene was generated by screening
a genomic library (derived from a human fibroblast cell line) with an MGMT cDNA
probe.

Twenty MGMT genomic clones were isolated, mapped with restriction
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enzymes (RE) and aligned, yielding a map of the gene containing four translated
exons spread over >80 kb. Several regions of the cloned MGMT gene with an
overabundance of potential methylation sites (CpG dinucleotides) were identified
with RE that recognize and cleave DNA at various CpG containing sequences.
These and other regions across the body of the MGMT gene were then used to
analyze MGMT gene methylation in human glioma cells.
To determine if methylation in the body of the gene correlates with MGMT
expression, the methylation status of CpGs throughout the body of the MGMT gene
were examined in nine human glioma cell lines exhibiting a wide range of MGMT
expression. Methylation in the body of the MGMT gene was analyzed by Southern
blot analysis of glioma DNA digested with methylation sensitive REs. All of the
MGMT gene regions tested were methylated in the MGMT expressing (MGMT+)
glioma cells and relatively unmethylated in the nonexpressing cells (MGMT-).
Quantitative analysis of methylation at an intron I CpG demonstrated graded
methylation and a strong, positive correlation between methylation and glioma
MGMT mRNA levels. These results suggest that methylation is uniform over the
entire body of the MGMT gene and correlates in a direct, graded fashion with
MGMT expression. This correlation is consistent with an indirect mechanism by
which uniform methylation over the body of the MGMT gene may influence
chromatin structure and hence MGMT expression.
To determine if the association between methylation in the body of the
MGMT gene and MGMT expression is mediated by changes in chromatin structure,
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the accessibility of RE to the MGMT gene within intact nuclei was assessed. The
unmethylated body of the MGMT gene was clearly more accessible to RE in nuclei
from all MGMT- glioma cell lines tested relative to the methylated gene in nuclei
from MGMT+ cells.

The only accessible sites within the MGMT+ nuclei

corresponded exactly to the few sites that were also unmethylated. These
experiments demonstrate that methylation and chromatin structure in the body of
the MGMT gene are closely linked, and are likely involved in MGMT expression.
To determine if promoter methylation is also an important component of
MGMT expression, this dissertation research addressed the complex interactions
between methylation, chromatin structure, and in vivo transcription factor
occupancy in the MGMT promoter of glioma cells. The level of MGMT promoter
methylation, assessed by linker mediated PCR, was also graded across the cell lines
(at 21 of 25 CpGs tested), but correlated in an inverse, rather than direct fashion
with MGMT expression. The basal promoter in MGMT+ glioma cells was entirely
accessible to RE, suggesting that this region may be free of nucleosomes. The basal
promoter in MGMT- nuclei was entirely inaccessible to RE, supporting the idea that
methylation and chromatin structure in the promoter are also associated. Despite
the presence of the relevant transcription factors in all the cells examined, in vivo
footprinting showed DNA-protein interactions at 6 Spl binding sites and one novel
binding site in MGMT+ glioma cells but no such interactions in MGMT- cells. In
contrast to previous in vitro studies, these data indicate that Spl is an important
component of MGMT transcription.

The data also strongly suggest that
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methylation and chromatin structure, by determining whether Spl and other
transcription factors can access the MGMT promoter, set the transcriptional state
of the MGMT gene.
In summary, these data provide compelling evidence for the involvement of
methylation and chromatin structure, both in the promoter and body of the MGMT
gene, in the regulation of MGMT expression. If these factors are also critical in
glioma cells within tumors, the "accessible" chromatin in the MGMT expressing, and
hence BCNU resistant, glioma cells may be a good target for inhibition of MGMT
expression, possibly through triple helix formation.
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CHAPTER I
INTRODUCTION

Gliomas are the most prevalent form of primary brain cancer and include
tumors arising primarily from astrocytes, but also less frequently, from
oligodendrocytes and ependymal cells. All patients with gliomas eventually die from
their tumors, often within months or a few years of diagnosis, unless other diseases
predominate (Ransohoff, et al., 1991). Although the etiology of gliomas is unknown,
late age of onset, poor neurological status and significant residual tumor volume
following surgery are factors intimately associated with decreased length of survival
(Ransohoff, et al., 1991). As the incidence of gliomas is increasing in the United
States (Greig ..fi_fil., 1990), there is considerable interest in elucidating the
biochemical and genetic defects leading to glioma formation and malignant
progression, and in developing effective therapies to treat gliomas.
Gliomas are classified by neuropathologic criteria into stages of increasing
malignancy, from benign to anaplastic to glioblastoma multiforme (Ransohoff, et
al., 1991). These stages represent a continuum of glioma progression within each
patient, although many patients do not survive through the anaplastic stage.
Increased malignancy is closely associated with decreased survival time. Precise
molecular and cytogenetic changes occurring at each stage of glioma progression
have recently been described and may eventually be used in conjunction with the
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neuropathologic criteria for more accurate diagnosis of the degree of malignancy
(Collins and James, 1993).

Such accuracy in diagnosis is critical, as the

malignancy stage strongly determines the response to and usefulness of various
therapies currently used to treat gliomas (Weingart and Brem, 1993).
The initial treatment for gliomas is surgical removal of the tumor. However,
because these tumors have very irregular shapes and ill-defined borders, residual
tumor cells remain in the patient following surgery, and invariably, the tumor
recurs (Ransohoff, et al., 1991). Surgery is therefore followed with radiation therapy
and often chemotherapy in attempt to eliminate the residual tumor cells.
Gliomas are treated most effectively with the chemotherapeutic agent l,3bis(chloroethyl)-1-nitrosourea (BCNU)(Walker, et al., 1980). BCNU is useful in
treating brain tumors for two reasons. First, the lipid soluble nature of BCNU
molecules allows them to cross the relatively impermeable barrier between the blood
vessel interior and brain tissue (the blood-brain barrier) and reach the brain tumor
site (Rall, et al., 1962). Second, the chloroethyl group adducts at the 0 6-position
of guanine produced by BCNU rearrange to form DNA interstrand crosslinks that
are cytotoxic to rapidly dividing cells (Kohn, 1977; Ewig and Kohn, 1978; Erickson,
et al., 1978). Because the vast majority of normal brain cells are in a nondividing
state, BCNU is much more toxic to the tumor cells. Initially, responses to BCNU
(tumor stasis or partial tumor regression) are seen in approximately one-half of all
glioma patients treated with BCNU (Walker, et al., 1980). At undefined points
during or after recurrence however, the majority of these gliomas become resistant
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to BCNU chemotherapy, and the tumor progresses rapidly (Weingart and Brem,
1993).

Research designed at elucidating the mechanisms conferring BCNU

resistance in glioma cells is paramount for improving the currently ineffectual
treatment of resistant gliomas.
Seventy percent of human glioma cell lines and many human glial tumors
are resistant to the cytotoxic effects of BCNU (Kornblith,..n..fil. 1981; Sariban, et al.,
1987; Day, et al. 1990; Ostrowski, et al., 1991). BCNU resistance is conferred by the
DNA repair protein, 0 6-methylguanine DNA methyltransferase (MGMT) (Pegg,~
al., 1982; Tano, et al., 1990). MGMT removes the BCNU-induced chloroethyl group
adducts from 0 6-guanine in the glioma cell DNA, preventing the formation of
cytotoxic interstrand crosslinks (Erickson, et al., 1980). Thirty percent of BCNUsensitive brain tumor cell lines are devoid of the MGMT mRNA and MGMT protein
despite the presence of an intact MGMT gene (Day, et al., 1990, Ostrowski, et al.,
1991; Costello, et al., 1994). This and other observations suggest that the BCNUsensitive phenotype of these brain tumor cells appears to result, at least in part,
from suppression of MGMT gene transcription (Ostrowski, .Il_fil., 1991, Costello, et
al., 1994a). Examining factors that may suppress MGMT gene transcription is
essential for designing therapeutic strategies to overcome BCNU resistance in
MGMT-expressing brain tumors.
Transcriptional control of gene expression is mediated by a variety of
mechanisms including DNA cytosine methylation (reviewed in Jost and Saluz, 1993).
In the DNA of all human cells, a subset of cytosines in the dinucleotide CpG are
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modified by an endogenous methylating enzyme (Bestor, et al., 1988). Addition of
a methyl group to cytosines of a CpG is a normal DNA modification that plays a
central role in transcriptional regulation of gene expression (Jost and Saluz, 1993).
Regions of DNA known as CpG islands contain clusters of CpG dinucleotides
(relative to the majority of bulk DNA which is CpG-depleted) that are normally
maintained in the unmethylated state (Bird, 1986). Because the MGMT cDNA has
an overabundance of CpGs (Tano, et al., 1990), one or more of the MGMT exons
comprising the cDNA sequence may be part of a CpG island. Processes which are
associated with abnormal de novo CpG island methylation such as tumorigenesis
(De Bustros, et al., 1988), viral transformation (Vertino, et al., 1993) and cell
culture (Antequera, et al., 1990), are also frequently associated with loss of MGMT
gene expression (Green, et al., 1990; Fornace, et al., 1990). Abnormal methylation
of potential MGMT gene-associated CpG islands could therefore be one mechanism
by which transcription of the MGMT gene is suppressed. Indeed, preliminary
evidence suggests that the methylation status of MGMT exons is altered in virtually
all MGMT nonexpressing (MGMT-) cell lines tested (Pieper, et al., 1991; Wang, et
al., 1992). The purpose of my dissertation research is thus to determine the
relationship between cytosine methylation and MGMT expression in human brain
tumor cells. I have proposed three specific aims to examine this relationship:

Aim 1: To isolate regions of the MGMT gene that contain CpG island
characteristics.
Aim 2: To determine the relationship between the methylation status of potential

MGMT gene-associated CpG islands and MGMT gene expression in human glioma
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cells.
Aim 3: To examine the mechanism by which methylation may influence MGMT
expression in human glioma cells.

The hypothesis that this dissertation research attempts to validate is that
glioma cells regulate expression of the MGMT gene by virtue of differential
methylation of MGMT gene-associated CpG islands. Methylation of the CpG island
regions, through methylated DNA binding proteins, alters the local chromatin
structure such that accessibility of other proteins necessary for transcription of the
MGMT gene is altered.
Understanding the relationship between cytosine methylation and MGMT gene
expression is important because it may ultimately be useful in the development of
therapies designed to inhibit MGMT expression. Inhibition of MGMT expression
followed by BCNU administration might then enhance the antitumor activity of
BCNU, significantly reduce the number of residual tumor cells following surgery
and thereby improve chemotherapy of BCNU-resistant gliomas.

CHAPTER II
LITERATURE REVIEW

Primm Brain Cancer
Approximately 16,000 new cases of primary brain cancer occur each year and
the incidence is increasing in the United States (RansohofT, et al., 1991). The
etiology of primary brain cancer is unknown. Primary brain cancer rarely, if ever,
metastasizes outside the central nervous system, yet many forms of primary brain
cancers are fatal (Weingart and Brem, 1993).
Gliomas are the most prevalent form of primary brain cancer.

Gliomas

include tumors arising predominantly from astrocytes, but also less frequently from
oligodendrocytes or ependymal cells. All glioma patients die of their tumors within
months or a few years of diagnosis. The most important prognostic criteria for
increased length of survival for glioma patients are younger age of onset, better
neurologic status, and decreased residual tumor volume following surgical resection
of the tumor (RansohofT, et al., 1991).
Gliomas are classified in grades of malignancy according to neuropathologic
and genetic criteria.

Gliomas often progress from benign to anaplastic to

glioblastoma multiforme (GBM) within each patient, although many patients die
before the most malignant stage (GBM) is reached. At diagnosis, all gliomas are
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visible by magnetic resonance imaging (MRI). Neuropathologically, benign tumors
are identified by the presence of microcysts and uniformly sized nuclei, while
anaplastic gliomas are identified by hyperplasia of blood vessel endothelial cells
within the tumor, and GBMs are identified by the presence of geographic necrosis
(Kornblith, et al., 1985). Recently, identification of specific genetic abnormalities
occurring at high frequencies within each of the neuropathologically-defined
malignancy stages have yielded genetic definitions of glioma progression. The
genetic changes identified in gliomas involve deletions, gene amplifications, and
mutations, with many of the changes imparting a growth advantage in the tumor
cell. Regions of chromosomal deletion are thought to involve the loss of tumor
suppressor genes, whereas gene amplifications in gliomas are exclusively associated
with oncogenes.

Mutations within chromosomes may involve either tumor

suppressor genes or oncogenes. Genetic changes found at similar frequencies in all
stages, such as deletions within chromosome 13q, 17p and 22q (James, et al., 1988;
Fults, et al., 1990), may be related to tumorigenesis and likely occur early in tumor
progression. Progression from benign to malignant glioma is accompanied by
additional deletions, within chromosome 9p (Miyakoshi, et al., 1990) and 19q (vonDeimling, et al., 1992), mutations in the tumor suppressor gene p53 (James, et al.,
1989), and/or MDM2 gene amplification (Collins and James, 1993).

Genetic

changes found only in later stages (GBM), such as complete loss of one copy of
chromosome 10, deletions with lOp and lOq (Karlbom, et al., 1993), and
amplification of the epidermal growth factor receptor (in 40% of all
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GBMs)(Libermann, et al., 1985), may be exclusively involved in malignant
progression. The frequent loss of one copy of chromosome 10 in GBMs is especially
relevant to this dissertation, as the MGMT gene resides on this chromosome
(Rydberg, et al., 1990; Natarajan, et al., 1992). Genetic analysis of gliomas in
conjunction with neuropathology may thus provide for more accurate diagnosis of
malignancy stage. Such accuracy in diagnosis is critical, as the malignancy stage
strongly determines the response to, and usefulness of, various therapies currently
used to treat gliomas.
The standard therapy for gliomas involves surgical removal of the tumor,
followed by radiation therapy, and often chemotherapy. While there are no curative
therapies available, surgical excision of gliomas is the treatment most clearly
associated with increased survival. However, gliomas are nonencapsulated tumors
and grow in a highly irregular, multidirectional fashion making complete surgical
resection impossible. Radiation and chemotherapy are therefore used to eliminate
residual tumor cells following surgery. Radiation treatment of gliomas also has
survival benefit, but recurrent gliomas and especially GBMs eventually become
unresponsive to further radiation therapy (Weingart and Brem, 1993). A variety of
chemotherapeutic agents have been tested for efficacy against gliomas, with initial
responses (tumor stasis or partial tumor regression) to several agents observed in
approximately 50% of glioma patients (Wilson, et al, 1970; McVie, 1993). As with
radiation therapy, gliomas also become unresponsive or resistant to chemotherapy.
Understanding and eventually inhibiting the mechanisms by which glioma cells

9

become resistant to chemotherapy is a current goal of cancer research.
Understanding these resistance mechanisms relies first on a clear knowledge of the
mechanisms by which the chemotherapeutic agents exert their cytotoxicity and
antitumor activity.
Chloroethylnitrosoureas (CENU) are a class of chemotherapeutic agents, of
which 1,3 bis(2-chloroethyl)-l-nitrosourea (BCNU) is the most commonly used and
most effective antitumor agent against gliomas (Wilson, ..e!.J!l, 1970; Walker, ..rt...al.,
1980). BCNU is a lipid soluble DNA alkylating agent, and when administered
intravenously to glioma patients, can easily cross the blood-brain barrier to reach
the tumor site (Rall and Zubrod, 1962). BCNU spontaneously decomposes under
physiological conditions to form a chloroethylating moiety and a carbamoylating
moiety (Tong, et al., 1982). The chloroethylating moiety forms several DNA adducts
including frequent N7-hydroxylethyl and N7-chloroethyl adducts on guanines and
much less frequent 0 6-chloroethyl adducts on guanines (Tong, et al., 1982). A wealth
of data indicates that the 0 6-chloroethyl group adducts on guanine are the adducts
most relevant to the cytotoxicity induced by BCNU (reviewed in Erickson, 1991).
Over a period of several hours, the 0 6-chloroethyl adducts undergo an
intramolecular rearrangement to form a cyclized intermediate, 0 6-N1-ethanoguanine,
and finally, through interaction with the cytosine on the complementary DNA
strand, form a guanine-N1-cytosine-N3 DNA interstrand crosslink (Tong, et al.,
1982). The frequency of DNA interstrand crosslinks correlates well with degree of
BCNU-induced cytotoxicity, supporting the idea that the crosslink is a relevant
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cytotoxic lesion (Erickson, et al., 1980). Few if any BCNU-induced DNA interstrand
crosslinks are formed in BCNU-resistant human glioma cell lines and xenografts.
Accordingly, a great deal of research has been directed towards elucidating the
mechanism by which resistant cells prevent BCNU-induced crosslink formation.

0 6-Methylzmanine DNA Methyltransferase (MGMT)

Initial investigations of mechanisms of CENU toxicity and CENU-resistance
were significantly advanced by several studies in the late 1970s and early 1980s.
After it was established that the alkylating moiety ofCENUs was capable of forming
DNA interstrand crosslinks (Kohn, 1977; Ewig and Kohn, 1978), high levels of
CENU-induced crosslinks were observed in CENU-sensitive human colon carcinoma
cells (BE) but few or no crosslinks were detected in a CENU-resistant colon tumor
cell line (HT29) (Erickson et al., 1978). The relationship between response to
CENU and presence of DNA interstrand crosslinks was demonstrated in a dosedependent fashion with at least four different CENU (including BCNU) (Erickson,
et al., 1980, 1980a). It was proposed that the lack of crosslinks in CENU-resistant
cells was due to a DNA repair mechanism operating in these cells but absent from
CENU-sensitive tumor cells (Ewig and Kohn, et al., 1978; Erickson et al., 1980a).
In 1980, the CENU studies converged with other studies examining repair of
DNA damage produced by the DNA methylating carcinogen N-methyl-N'-nitro-Nnitrosoguanidine (MNNG)(Day, ~., 1980). Human tumor cell lines tested for
their ability to repair, and hence reactivate, MNNG-damaged adenovirus fell into

11

two groups.

One group of tumor cell lines reactivated the MNNG-damaged

adenovirus and was designated methylation repair positive, or Mer+. The group
that was incapable of adenovirus reactivation, and hence incapable of methylation
repair was termed methylation repair negative, or Mer-. Soon after this report, it
was demonstrated in blinded studies that the CENU-resistant cell lines, which were
capable of preventing CENU-induced crosslinks, were also Mer+ and the CENUsensitive cell lines were Mer- (Erickson, et al., 1980). Additional studies firmly
defined the Mer phenotype on the basis of a cell's ability to reactivate MNNGtreated adenovirus, prevent CENU-induced DNA interstrand crosslinks, and repair
0 6-methylguanine in DNA (Day, et al. 1980a, and Erickson, et al., 1980a). A DNA

repair protein responsible for the CENU resistance, termed 0 6-methylguanine DNA
methyltransferase, was subsequently identified in mouse liver (Bogden, et al., 1981),
rat liver (Pegg, et al.,1983), and normal human liver (Pegg, et al., 1982).
0 6-methylguanine DNA methyltransferase (MGMT) is a major determinant

in the sensitivity of glioma cells to CENU. MGMT confers resistance to CENU
(and other agents that alkylate the 0 6-position of guanine) by transferring alkyl
group adducts, including chloroethyl adducts, from the 0 6-position of guanine in
DNA to a cysteine acceptor site at cys-145 within the MGMT protein (reviewed in
Pegg, 1990). MGMT can also form covalent interactions with the CENU-DNA
cyclized intermediate (Gonzaga, et al., 1992). The transfer reaction restores guanine
to its unmodified state, thus preventing crosslink formation, and inactivates one
MGMT molecule per lesion.

MGMT does not require any other proteins or
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cofactors for the transferase activity in vitro. Although CENU resistance may
involve mechanisms other than MGMT in a limited number of cases (Karran and
Stephenson, 1990; Bronstein, et al., 1992; Branch, et al., 1993), the demonstration
that specific pharmacologic inhibition of MGMT sensitizes CENU-resistant cells
(Zlotogorski and Erickson, 1983 and 1984; Dolan, .rt_fil., 1990) clearly establishes
a dominant role for MGMT in conferring CENU resistance. This and other studies
(Futscher, et al., 1989; Marathi, et al., 1993) also demonstrate the feasibility and
usefulness of inhibiting MGMT for therapeutic benefit.
The cDNA for the 0 6-methylguanine-DNA methyltransferase has been cloned
(Tano, et al., 1990; Hayakawa, et al., 1990; Rydberg, et al., 1990), the chromosomal
location of the MGMT gene defined (Rydberg, et al., 1990; Natarajan, .!1.Jtl., 1992)
and the presence of MGMT mRNA verified in Mer+ cells (Rydberg, et al., 1990).
The human MGMT cDNA was first isolated by transforming repair deficient
bacteria with a cDNA library made from a Mer+ cell line, followed by phenotypic
rescue of repair proficient cells in MNNG-containing media (Tano, et al., 1990).
The protein coding portion of the MGMT cDNA is 624 nt and is flanked on the 5'
end by at least 96 nt and 224 nt on the 3' end. The cDNA sequence also contains
a consensus sequence for poly-A tail addition. The predicted amino acid sequence
does not contain any clear nuclear localization signals as would be expected for a
DNA repair protein. The MGMT protein is, however, localized exclusively in the
nucleus (Ayi et al., 1992).
The level of MGMT expression in normal human tissue is cell type specific,
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tissue specific and varies among individuals. Normal human brain and lung are
low in MGMT activity and mRNA relative to liver, which has the highest level of
MGMT in any normal tissue tested (Pegg, 1978; Citron, et al., 1991). Different cell
types within the liver (Swenberg, et al., 1982) and kidney (Wani, et al., 1992) have
10-fold variations in MGMT levels. For example, MGMT mRNA is highest in distal
tubular and glomerular epithelial cells and low in the Bowman's capsule cells,
collecting and proximal tubular cells. The MGMT expression levels in specific cells
of the liver and kidney correlate well with variations in persistence of 0 6alkylguanine lesions in these cells following exposure to alkylating agents. It has
not been determined whether the levels of MGMT vary in a cell type specific
manner in normal human brain (eg. neurons versus glia). MGMT measurements
in peripheral blood lymphocytes showed a 7-fold interindividual variance
(D'Ambrosio, et al., 1990), although no such interindividual variation was seen in
MGMT mRNA levels in human kidney cells (Wani, et al., 1992).
The level of MGMT expression in human glioma tissue is highly variable. A
one hundred-fold variation in MGMT activity among 27 unrelated glioma samples,
including 22% with no detectable MGMT activity, was reported in one study
(Citron, et al., 1991). Another study of 60 glioma samples showed a similar
frequency (27%) of MGMT deficient gliomas (Silber,..tl.fil., 1993). These studies are
consistent with the reported 20-30% of MGMT deficient human glioma cell lines
(Ostrowski, et al., 1991). The frequency of MGMT deficient gliomas is not a
universal finding however (Wiestler, et al., 1984) and even the existence of such
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tumors is debated by some researchers.
MGMT expression is presumed, but not proven, to be regulated at the
transcriptional level. Although all the glioma cell lines tested have an intact
MGMT gene, the glioma cell lines devoid of MGMT activity are also lacking the
MGMT protein, as measured by western blot analysis, and MGMT mRNA, as
measured by northern blot analysis (Ostrowski, ..H__fil., 1991). Using the more
sensitive PCR technique however, small amounts of MGMT mRNA are detectable
in populations of some Mer- cell lines, indicating that MGMT transcription may
occur at very low levels, or at higher levels with a concomitant decrease in mRNA
stability, in these cell lines (Pieper, et al., 1990). A defect at the transcriptional
level appears more likely though, as there were no differences in MGMT mRNA
stability in cell lines with vastly different levels of MGMT mRNA (Kroes and
Erickson, 1992). Attempts to measure transcription rates by detection of MGMT
heteronuclear RNA (hnRNA), either through nuclear run-on assays or PCR, have
been unsuccessful, even in cells with high levels of MGMT mRNA (Kroes and
Erickson, 1992; Russell Pieper, personal communication). This may indicate that
in MGMT expressing cells, the rate of MGMT transcription is too slow to detect
and/or that other events such as processing of MGMT hnRNA occur rapidly after,
or even concurrent with, transcription. Consistent with transcriptional differences
in MGMT expression, a recent study has demonstrated that the level of cytosine
methylation in MGMT exons is consistently decreased in MGMT deficient tumor
cells (Pieper et al., 1991).
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cytosine Methylation and Gene Egression

Methylation of the CS-position of cytosine is a normal, covalent DNA
modification found in all mammalian cells. Methylation occurs exclusively at the
dinucleotide CpG and approximately 60% of all CpGs are methylated (Bestor, et al.,
1984). Cytosine methylation is accomplished by enzymatic transfer of a methyl
group from S-adenosylmethionine to a cytosine within a CpG.

The preferred

substrate for the enzyme, cytosine methyltransferase (MTase), is hemimethylated
DNA (Gruenbaum, et al., 1982). The methylation reaction occurs during DNA
replication (Leonhardt, et al., 1992), allowing methylation patterns to be transmitted
in a stable manner through each cell generation, and is thus termed maintenance
methylation. In mammalian development, establishment of methylation patterns
occurs in the postimplantation embryo by de novo methylation. Although the
mechanism responsible for de novo methylation is unknown, establishment of
appropriate methylation levels is critical for normal development and survival in
mammals (Li, et al., 1993).
The distribution of the potential methylation site, CpG, is nonrandom. The
overall genome is depleted ofCpGs 5-fold from the expected CpG frequency, derived
from base composition alone (McClelland and lvarie, 1982). The genome-wide CpG
depletion is thought to result, at least in part, from the spontaneous deamination
of methylated cytosines to thymine (Salser, 1977).

This mechanism of CpG

depletion is consistent with the observed overabundance of TpG and ApG
dinucleotides in the genome. Accordingly, methylation and subsequent deamination

16
tend to deplete potential methylation sites, and conversely, CpGs are more likely to
be preserved through many cell divisions by being maintained in the unmethylated

state.
In contrast to the majority of the genome, short segments of DNA, together
comprising approximately 1% of the genome, have the theoretically expected
frequency of CpGs and are termed CpG islands. CpG islands are defined as
regions of DNA characterized by the following three features: 1) 0.3 to 3.0 kb in
length, 2) the expected frequency of CpG dinucleotides (compared to the 5-fold
CpG depletion seen in the genome overall), and 3) a guanine + cytosine (GC)
content of >50% (compared to <40% in the genome overall) (Gardiner-Garden and
Frommer, 1987).

Additionally, CpG islands are normally maintained in the

nonmethylated state, thus increasing the likelihood that these CpGs will be
preserved (Bird, 1986). Approximately 45,000 CpG islands are present in the
human genome and, similar to CpGs, are distributed non-randomly throughout the
genome (Antequera and Bird, 1993). The non-random distribution and maintenance
of CpG islands in the unmethylated state implies that there is some functional
importance associated with CpG islands.
Virtually all known CpG islands are associated with genes, predominantly in
the 5' region of genes, but also less frequently in 3' gene regions (Gardiner-Garden
and Frommer, 1987). The promoters for all known housekeeping genes (genes
essential for cell survival) are within, or part of, a CpG island. Forty-five thousand
of the estimated 80,000 genes in the human genome are likely associated· with a
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CpG island (Antequera and Bird, 1993). Because the MGMT gene is considered a
housekeeping gene it is likely that the MGMT promoter is associated with a CpG
island. Because the MGMT cDNA is very GC rich and has an overabundance of
CpGs, it is possible that one or more of the MGMT exons may also be part of a
CpG island.
A variety of evidence indicates that CpG islands have a critical role in the
regulation of genes with which they are associated. CpG islands invariably contain
nucleosome free regions that are very accessible to diffusible factors (Tazi and Bird,
1990).

Such accessible DNA sequences are essential for interaction with

transcription factors and maintaining a transcriptionally active state. Although the
nucleotide sequence among individual CpG islands is highly variable, most CpG
islands have consensus sites for a common set of transcription factors (eg. Spl),
and these sites are indeed essential for transcription of the associated gene (Pugh
and Tjian, 1990). Although CpG islands are usually unmethylated, the de novo
methylation of CpG islands does occur, concomitant with suppression of
transcription from the associated gene. The methylation status of CpG islands is
therefore a critical parameter of gene regulation.
Changes in the methylation status of CpGs within CpG islands and CpGs
located in non-island sequences may occur as a result of one or several normal (X
chromosome inactivation, imprinting, tissue specific gene expression) or abnormal
(tumorigenesis, viral transformation, cell culture) processes (reviewed in Jost and
Saluz, 1993). The aberrant methylation changes noted in many, but not all, tumor
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cells are described as widespread hypomethylation (Goelz and Vogelstein, 1985) and
regional hypermethylation (De Bustros, .n...fil,, 1988). Widespread hypomethylation
refers to an overall decrease in the level of methylated CpGs in the genome and
probably involves gene and non-gene sequences. Regional hypermethylation in
tumor cells occurs at normally unmethylated CpG islands.

The frequency of

methylation changes in tumor cells is not clear, although one study of the calcitonin
gene-associated CpG island demonstrated hypermethylation in only 2 of 31 chronic
myelogenous leukemia (CML) patients in less advanced stages (Nelkin, et al., 1991).
Hypermethylation was detected much more frequently (11 of 12 patients) in
advanced stage CML. This study suggests that methylation changes may contribute
to tumor cell progression. In contrast to CML, colon cancer patients have frequent
abnormal CpG island methylation in the calcitonin gene and chromosome 17p (a
region thought to harbor a tumor suppressor gene) in the early, benign stages
(Silverman, et al., 1989), suggesting that methylation changes may also contribute
to tumorigenesis. Gliomas have not been tested for similar changes in methylation.
Tumorigenic transformation produced by viral infection or by transfection of
oncogenes also alters methylation within affected cells (Vertino,

~.,

1993).

Methylation changes in cultured cell lines have also been noted, with an estimated
one-half of all CpG islands being subject to aberrant hypermethylation (Antequera,
et al., 1990). The mechanisms involved in, or leading to, abnormal changes in
methylation are not defined, although increased expression of the MTase gene has
been noted in some tumor cells (El-Deiry, et al., 1991).

As the MTase is a
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maintenance methylase, overexpression of MTase alone cannot account for the high
level of de novo methylation in tumor cells or cell lines.

In X chromosome

inactivation, tumorigenesis, viral transformation, and cell culture, the documented
methylation changes are also accompanied by changes in expression of the
associated gene. Since the tumorigenic state, cell culture, and viral transformation
are conditions also associated with frequent loss of MGMT gene expression, it
seems likely that the methylation status of the MGMT gene, possibly including
MGMT gene-associated CpG islands, is altered in at least some of the cells in these
conditions.
In the majority of genes studied, the methylation status of CpGs in the
promoter correlates in an inverse, all-or-none fashion with gene expression.
Whether the methylation status of a given promoter is a result of normal or
abnormal processes, methylated promoters are associated with inactive genes and
unmethylated promoters are associated with active genes (reviewed in Saluz and
Yost, 1993).

During X-chromosome inactivation for example, the CpG island

promoter for the phosphoglycerate kinase (PGK-1) gene becomes methylated at 119
of 121 CpGs on the transcriptionally inactive X chromosome but remains
unmethylated at all 121 sites on the active X chromosome

(Pfeifer,~.,

1990).

The inactivation of the X-linked genes precedes the CpG island methylation
however, indicating that for these genes, methylation may serve to "lock in" the
transcriptionally inactive state rather than cause gene silencing. On the other hand,
methylated, inactive genes (including PGK-1) can be reactivated by exposing cells
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to the demethylating agent 5-azacytidine. Additionally, a large number of studies
have demonstrated that in vitro methylated genes are transcriptionally inactive
when transfected into cells, whereas the unmethylated, transfected genes are
expressed (Stoger, et al., 1993; Boyes and Bird, 1992). In general, unmethylated
promoters are necessary but not sufficient for gene expression.
As opposed to promoter methylation, the relationship between the methylation
status of CpGs in the body of genes and gene expression is poorly defined. A direct,
rather than inverse, correlation between body methylation and gene expression has
been noted in several studies. For several X chromosome linked (Wolf, .§.J!l., 1984)
and autosomal (Razin and Riggs, 1980; Stein, et al., 1983) genes, extensive
methylation of over entire body sequences is associated with active transcription.
In the transcriptionally inactive state, the body of these genes is variably
methylated, but generally much less methylated than the body of active genes. The
body of the gene encoding the developmentally regulated transplantation antigen H2K is unmethylated in cells that do not express H-2K, but upon differentiation, the
H-2K gene becomes methylated coincident with transcriptional activation (Tanaka,
et al., 1983). The active H-2K gene can then be suppressed by 5-azacytidine-induced
demethylation of the body of the gene, further strengthening the direct relationship
between body methylation and gene expression.

In other genes such as the

maternally imprinted Igt2-r gene, methylation of the body of the gene correlates
directly with expression, but only in a very specific region (2 kb of 130 kb
analyzed)(Stoger, et al., 1993). In vitro methylation of CpGs in the body of genes,
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without promoter methylation, influences gene activity (Keshet, et al., 1985). In yet
other genes, no obvious relationship is detected between methylation and gene
expression (McKeon, .n._m., 1982).

Although a mechanism by which methylation

in the body of genes influences gene expression has not been defined, the conserved
methylation status of CpGs in the body and promoter of many genes suggests that
there is functional importance associated with methylation of both of these regions.
Additionally, the direct association between methylation and gene expression in the
body of genes and inverse association in promoters suggests that body methylation
and promoter methylation, by different mechanisms, may be involved in setting the
expression state of genes as active or inactive.
Two models have been proposed to mediate the relationship between
methylation and gene expression (Antequera, et al., 1989). The first, "direct model"
postulates that cytosine methylation interferes directly with the binding of
transcription factors to their specific recognition sequence in regulatory regions of
DNA.

This model is supported by experiments comparing the transcriptional

activity of methylated to nonmethylated cyclic adenosine monophosphate (cAMP)
response element (CRE) sequence in cloned DNA. Methylation of a single cytosine
within the CRE was sufficient to abolish both binding of the CRE binding protein
to CRE and transcriptional activation of genes linked to CREs (Sanae and
Schaffner, 1989). This mechanism however, is obviously limited to CpG-containing
binding sites and is irrelevant to transcription factors such as Spl, whose binding
is methylation independent (Harrington, et al., 1988). A second, "indirect model"

22
suggests that cytosine methylation interferes with transcription via proteins that
bind specifically to methylated DNA (MeCPs) and alter the local DNA conformation
such that these DNA regions become transcriptionally inactive (Antequera, .n._ru.,
1989, 1990). This model is supported by the identification of four such proteins
that bind selectively to DNA containing methylated cytosines (Wang, et al., 1986;
Antequera, et al., 1989; Jost and Hofsteenge, 1992; Lewis, et al., 1992). Additional
evidence for the indirect model comes from experiments using methylation sensitive
DNA restriction enzymes (17). The DNA recognition sequence of the restriction
enzyme Mspl (CCGG) contains a potential methylation site (CpG dinucleotide).
While Mspl cleaves naked DNA (no protein) irrespective of methylation, it does not
cleave DNA at methylated CCGG sequences contained within isolated, intact nuclei
(protein bound DNA), suggesting that MeCPs, if present, block Mspl accessibility
to the DNA. The interrelationship of MeCPs with other chromosomal proteins (eg.
histones) in the formation or maintenance of the methylation-related inactive
chromatin is not understood.

Methylation-related chromatin structures could

explain why many genes, including MGMT, are not expressed in cells that contain
all the relevant transcription factors (Antequera, et al., 1989).
While methylation clearly can be involved in setting the state of gene
activation/inactivation, a limited amount of studies suggest that graded
methylation, both in promoter and body regions of genes may be associated with
more graded levels of gene expression. One study used an artificial system in which
the entire human a-globin gene was methylated to low, intermediate and high levels
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in vitro and then transfected into HeLa cells (Boyes and Bird, 1992). In this study,
both the level of methylation and binding of MeCPs correlated inversely with
expression of the transfected Q-globin gene. Similar results were seen with SV40
promoter containing constructs methylated in vitro and transfected into mouse cells
(Levine, et al., 1992).

These studies raise the possibility that methylation, in

addition to being a mechanism associated with regulation of gene expression in an
all or none fashion, may also be associated with subtle changes in the level of gene
expression.

CHAPTER III
METHODS

Cell Culture

The ten glioma cell lines used were established from grade III-IV human
astrocytomas and glioblastomas. The glioma cell lines used were A1235, CLA, CRO,
NAT (L. Erickson, Loyola University Medical Center, Maywood, IL.) SF763, SF767
(Brain Tumor Research Center, University of California, San Francisco, CA),
Hs683, T98, U138, and U373 (purchased from American Type Culture Collection).
The cell lines were all grown in a-minimal essential medium (Hyclone Laboratories)
with 10% bovine calf serum (Hyclone), glutamine, vitamin B12/Biotin, sodium
pyruvate, gentamycin and nonessential amino acids. The cell lines were maintained
in log phase growth at 37°C in a 95% air;5% C02 atmosphere.

MGMT cDNA probe SJ'llthesis - An MGMT cDNA was obtained by polymerase
chain reaction (PCR) amplification of reverse transcribed T98 RNA using two
MGMT-specific oligonucleotides. First strand synthesis was performed in a 20 µl
reaction containing 1 µg of T98 mRNA, 1 X PCR buffer (10 mM Tris-Cl, pH 8.3/50
mM KCl/3.0 mM MgC12/0.01% gelatin), 1 mM each of dCTP, dATP, dGTP and
dTTP (Perkin Elmer Cetus (PEC) ), 0.32 µg oligo dT (Bethesda Research
24
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Laboratories (BRL)) and 200 U Moloney murine leukemia virus reverse
transcriptase (BRL). The reaction was incubated at 25°C for 10 min, 37°C for 1 hr,
and 95°C for 10 min, followed by cooling on ice.

10 X PCR buffer (without

magnesium), dNTP mix and ddH20 were added to give a final volume of 100 µl, 200
µM each dNTP, and a 1 X PCR buffer concentration. Fifty pmol each of two

primers complementary to the published MGMT cDNA (Tano, li...fil., 1990) were
added

to

the

reaction.

The

AAGGTACCGTTTGCGACTTGGTACTTG-3'

5'

and

TAGTCGACCATCCGATGCAGTGTTACACG-3'.

primer
the
Both

3'

was

primer

primers

5'-

was
contain

5'7

nonMGMT-complementary nt at the 5' end (for cloning purposes). Three units of
Taq polymerase (Perkin, Elmer, Cetus) were added and the reaction was amplified
by PCR (95°C for 5 min followed by 30 cycles of 95°C for 30 sec, 55°C for 30 sec,
and 72°C for 45 sec and a final incubation at 72°C for 10 min). The products of
the reaction were electrophoresed through a 1.5% agarose gel and a gel slice
containing the single PCR product (730 bp) was removed. The DNA was isolated
from the gel slice by centrifugation (5 min, 12000 RPM) through glass wool (Alltech,
Deerfield, II.), and was ethanol precipitated, and resuspended to 10 ng/µl in ddH20.
Twenty-five ng of the purified amplification product was used to synthesize a
radiolabelled MGMT cDNA probe by the random primer method (Feinberg, et al.,
1984) with [a-32P] dCTP (specific activity 3000 Ci/mmol, Amersham, Arlington
Heights, IL.). The specific activity of the labelled MGMT cDNA was typically > 109
cpm/µg. Human histone H3.3 cDNA was generated in the same manner as the
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MGMT cDNA except with the following histone-specific primers: 5' primer, 5'·
CCACTGAACTTCTGATTCGC-3'and3'primer,5'-GCGTGCTAGCTGGATGTCTT3'.

Genomic Library Screenin& and Restriction Emme Mappin&
A genomic library constructed from the DNA of a human fibroblast cell line
(Wl38) inserted in the phage vector Lambda FIX II (Stratagene, La Jolla, CA.) was
screened according to the manufacturer's protocol. Approximately 1 X 106 plaque
forming units (PFU) were screened with the MGMT cDNA probe as follows: In
each of 20 tubes, approximately 50,000 PFU were mixed with 600 µl of O.D.600

=0.5

PLKl 7 bacteria, incubated for 15 min at 37°C, and added to 3 ml of 48°C top agar
(LB broth (Difeo), 0.7 % agarose (FMC).

This mixture was poured on room

temperature LB plates and incubated for 6 - 14 hours at 37°C, and then at 4°C for
2 hr. Twenty bacterial plates each with 50,000 of these plaques were used in the
primary library screening.
In order to test the DNA from each plaque for hybridization to the MGMT
cDNA, two nitrocellulose membranes were sequentially laid on the plates for 60 sec
and then removed. Each filter was then submerged sequentially in denaturing
solution (1.5 M NaCl/0.5 M NaOH, 2 min), neutralizing solution (1.5 M NaClf0.5
M Tris-Cl pH 8.0, 5 min) and rinsing solution (0.2 M Tris-Cl pH 7.5/2X SSC). The
filters were air dried on Whatman 3MM paper and the DNA was crosslinked to the
filter by U.V. irradiation (Stratalinker, Stratagene). These duplicate membranes
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were hybridized in a standard hybridization buffer (50 % formamide/10 % dextran
sulfate/5X SSPE/EDTA buffer/1% SDS/250 µg per ml of denatured salmon sperm
DNA/lX Denhardts solution) with a uniformly
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P-labelled MGMT cDNA. The

filters were washed under stringent conditions [0.1 X standard saline phosphate
(SSPE) (lX SSPE

= 180 mM NaCl/10 mM sodium phosphate/I mM EDTA, pH

7.0)/0.1% sodium dodecyl sulfate, 60°C for 5 min] in a Disc-Wisk washing system
(Schleicher and Schuell, Keene, NH.), dried and autoradiographed (12 - 24 hr with
intensifying screens).
The autoradiograph was lined up with the original bacterial plate to
determine which phage plaque corresponded to the positive signal on the
autoradiograph. Identical hybridization signal on the autoradiograph of duplicate
filters confirmed the specificity of the hybridization. Twenty plaques corresponding
to positive signals were removed from the LB plate with the wide end of a pasteur
pipette. Bacteriophage particles were eluted (4°C, overnight) into 100 µI - 1 ml SM
buffer (1 L

= 0.1 M NaCI/8.1 mM MgS04/50 mM Tris-HCl pH 7.5/.01% gelatin).

The 20 positive phage populations isolated in this way were then purified through
secondary and tertiary screening carried out in the same manner as the primary
screening.
The twenty clones were divided into four groups based on hybridization to one
of four MGMT cDNA restriction fragments. The four cDNA fragments, listed 5' to
3', are as follows: An 154 bp Pvull fragment spanning nucleotides 1 - 154 of the
PCR amplified cDNA; a 207 bp Hinfl fragment spanning nucleotides 100 - 307; an
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107 bp Hinfl/Hhal fragment spanning nucleotides 307 - 414; and an 137 bp Sstl
fragment spanning nucleotides 584 - 721.
Within each genomic clone, the MGMT gene fragment is internal to 17 bp T3
and T7 promoter sequences which are in turn flanked by various restriction enzyme
(RE) sites, including Notl sites. Cutting the entire recombinant DNA molecule with
Notl therefore excises a DNA fragment containing the MGMT gene fragment
flanked by the T3 and T7 promoter sequences. In order to arrange all of the
isolated MGMT gene fragments into a continuous length of DNA covering the
coding portions of the MGMT gene, the Notl-excised DNA from each different
phage was analyzed by RE mapping.
RE (BamHI, Hindlll and EcoRI,) maps of the twenty cloned MGMT gene
fragments were generated as follows: The MGMT gene fragments were cut from
phage vector DNA by complete digestion with Notl (5 U/µg DNA, Stratagene). The
DNA products of the Notl digest were then partially digested in separate reactions
with BamHI, Hindlll, or EcoRI, (0 U, .05 U, 0.5 U, 5 U, and 50 U, for 15 min, 37°C,
(BRL)) and analyzed by Southern blot (as described below) with a 32P end-labelled
T3 or T7 promoter primer (Stratagene). Rehybidization of these Southern blots
with a
clone.
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P-labelled MGMT cDNA identified MGMT exons within each genomic

The number and position of restriction sites within each clone (the

restriction map) were used to determine if the DNA fragments were overlapping or
discontinuous with respect to their positions in the genome. Eight genomic clones
with the minimal amount of overlap were then aligned to generate a discontinuous
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map of the coding sequences of the MGMT gene.

Analysis of MGMT Exons

Four exons were identified in the genomic clones by Southern blot analysis
with radiolabelled MGMT cDNA fragments (listed above). To facilitate sequencing
of two MGMT exons, the genomic DNA fragments containing the exons were
subcloned into plasmid vectors. A 4.8 kb BamHI/Hindlll fragment of genomic
clone le containing the 5'-most exon (designated exon 2) of the cDNA used, was
subcloned into the plasmid pGEM-3Zf (Promega, Madison, WI.), and a 2.8 kb
Notl/Nael fragment (from genomic clone 7c) containing a second exon (designated
exon 3) was subcloned into pBluescriptll SK+ (Stratagene).

The resultant

subclones were designated p5'BH and p7cNN, respectively. The exon regions of
these subclones were sequenced with MGMT cDNA primers using the dideoxy
sequencing method (Taq Track Sequencing System, Promega). Hybridization of a
32

P-labelled Hinfl/Hhal fragment of the MGMT cDNA (see above) to Southern blots

of genomic clone Sb identified a third translated exon, designated exon 4.
Nucleotides complementary to the MGMT cDNA within the 3'-most exon were
identified in cloned genomic DNA by PCR amplification (as described above) using
primers complementary to the 3' end of the MGMT cDNA (primer 1,
complementary to nucleotides 590-610, primer 2, complementary to nucleotides 776755). This region was designated exon 5.
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Generation of Intron Specific Probes
An intron 1 region, 5 kb 5' of exon 2, was derived from an EcoRI digest of

genomic clone ld. Following electrophoresis of the digestion products through a
0.5% low-melt agarose (FMC) gel, a 3.8 kb EcoRI fragment was cut from the gel and
recovered by centrifugation (5 min, 12,000 x g) through siliconized glass wool
(Alltech, Deerfield, IL.). A 3.8 kb EcoRI fragment, 10 kb 3' from exon 3 was used
as an intron 3-specific probe. An Eagl fragment, 4 kb 3' of exon 5, was used as a
probe to examine methylation at the 3' end of the MGMT gene. Approximately 25
ng of the intron fragments were used as templates for generating intron-specific
probes by random priming.

Identification and Sequencine of CpG Islands within Genomic Clones
Potential CpG islands within each MGMT genomic clone were identified by
RE mapping as described above except using CpG island-sensitive RE (BssHII,
Eagl, Nael, Nari, Notl, Smal, Sacll). Restriction sites for CpG island-sensitive REs
are rare in bulk DNA, but occur relatively frequently in CpG island DNA (Lindsay
and Bird, 1987). 0.5-3.0 kb clusters of the CpG island-sensitive RE sites thus
identified potential CpG islands within the 12-23 kb MGMT gene fragments. Three
MGMT gene regions containing clusters of these RE sites (designated region 1, 2,
and 3), all within one genomic clone (7c), were subcloned and sequenced to
determine if these regions had CpG island characteristics. The 5' - most region,
containing part of exon 3, was excised from the genomic clone 7c by digestion with
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Notl and Nael. The 2.6 kb Notl/Nael fragment was then ligated into Notl/Smalcut pBluescriptIISK + plasmid (Stratagene) in a 10 µl ligation reaction containing
o.7 units of T4 DNA ligase, lX ligase buffer, and an approximately 3:1 molar ratio
of insert to vector DNA. Following incubation at 14°C for 12 hr, the reaction was
diluted 1:5 with 10 mM Tris-HCL/1 mM EDTA pH 8.0, and 1 and 3 µl aliquots of
the diluted reaction were used to transform competent bacteria (DH5a) according
to the manufacturer's protocol (BRL). 9, 90, and 900 µl aliquots of transformed
bacteria were then spread onto separate LB bacterial plates containing 0.5 mM
IPTG (Fisher), 40 µg/ml X-Galactose (Promega), and 100 µg/ml ampicillin (Sigma).
Several white bacterial colonies were removed from the plates and used to inoculate
LB broth containing ampicillin. The inoculated LB broth was subsequently placed
in a 37°C shaking incubator (250 cycles/min.) for 8 -12 hr. 50 - 100 µg of the
recombinant plasmid DNA (p7cNN) was recovered from the transformed bacteria
(Quiagen minicolumn). To facilitate sequencing of relevant areas, p7cNN was
digested with Eagl, which removed a 1.2 kb Notl/Eagl fragment, and religated to
generate the 1.6 kb Eagl/Nael insert in p7cEN.
A 4.7 kb EcoRI fragment (middle of 7c) and 3.8 kb EcoRI fragment (3' in 7c)
of genomic clone 7C, which also contain clusters of the recognition sites for CpG
island sensitive restriction enzymes, were subcloned in a similar manner into EcoRI
digested pBluescript plasmid. To facilitate sequencing of regions of interest, these
subclones were further subcloned as 3.1 kb and 1.6 kb Smal/EcoRI fragments (for
the 4.7 kb middle subclone) and as 2.4 kb BssHII/Notl fragment (for the· 3.8 kb
subclone). A nucleotide sequence for each subclone was determined using the
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dideoxy sequencing method (Taq Track, Promega).

Northern Blot Analysis of MGMT mRNA
Total cellular RNA was isolated from each glioma cell line by a guanidinium
isothiocyanate lysis procedure (Chirgwin,n_fil., 1979). Twenty µg of RNA from each
glioma cell line was denatured by incubation at 50°C for 1 hr in a 21 µl reaction
composed of 3 µl of 7 M glyoxyl, 10.5 µl DMSO, 2.1 µl 0.1 M NaH 2P04 pH 6.8 and
5.4 µl RNA. The denaturing reaction was then briefly cooled on ice before addition
of 4 µl loading buffer (40'fo sucrose/0.25% bromophenol blue (BPB) ), Following
electrophoresis (100 V, 4.5 hr) in a 1% agarose gel (1.4 g agarose/140 ml 10 mM
NaP04 pH 6.8)

the RNA was transferred to a nylon membrane by capillary

blotting. The membrane was then soaked sequentially in 50 mM NaOH for 15 sec
and lX standard saline citrate (lX SSC

=0.15 M NaCl/15 mM sodium citrate, pH

7.0), 0.2 M Tris-HCl pH 7.5 for 30 sec. The RNA was fixed to the membrane by UV
crosslinking (Stratalinker) once the membrane had air dried. To confirm that the
RNA was intact, the 28s and 18s rRNA bands were visualized on the filter under UV
light. The membrane was prehybridized in standard prehybridization solution (same
solution as for library screening) for 4 hr at 42°C. Following addition of
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P-

labelled MGMT cDNA probe, the membrane was washed initially in lX SSPE/0.1%
SDS, 25°C for 15 min and then at 60°C, O.lX SSPE/0.1% SDS for 6 min in a Disc
Wisk apparatus. Relative hybridization of the probe to glioma RNA was determined
with a Betascope 603 blot analyzer (Betagen). Additionally, the membranes were
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autoradiographed for 4-8 days.
The membranes were subsequently stripped of bound probe by submersion in
a boiling solution composed of 1 % SDS, 10 mM Tris pH 8, 1 mM EDTA for 30
min.

After drying, the membranes were prehybridized and hybridized with a

radiolabelled histone H3.3 cDNA probe. Hybridization of the probe to histone H3.3
mRNA was visualized by autoradiography.

MGMT Protein Assay
The relative amount of MGMT DNA repair activity in each glioma cell line
was determined by an in vitro assay which measures the extent to which glioma cell
sonicates repair methyl group adducts at 06-guanine within a 32P-end-labelled 18 bp
DNA substrate (Wu, et al., 1987; Futscher, et al., 1989).
2-5X106 cells from each glioma cell line were centrifuged and the cell pellet
was washed twice with cold lX phosphate buffered saline (lX PBS = 0.137 M
NaCl/2.68 mM KCl/10.14 mM Na2HP04/1.76 mM KH 2P04, pH 7.4). The cells
were resuspended in 400 µl ice cold assay buffer (50 mM Tris pH 8.0/1 mM
EDTA/5 mM dithiothreitol/5% glycerol) and sonicated on ice in 12-5 sec bursts
(with 5 sec off time between each burst to prevent the sonicator probe from heating
the cell sonicates) of 0.3 relative output with a Virsonic cell disrupter (Virsonic).
Following centrifugation (12,000 RPM, 30 min) the protein concentrations of the
supernatants were determined spectrophotometrically. The extent of absorption of
595 nm light in a 1 ml solution composed of 1 or 2 µl aliquots of the supernatant
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from each glioma cell line, 200 µl protein assay dye reagent (Biorad, Richmond,
CA), and ddH 20 was measured spectrophotometrically and then converted to µg of
protein/µl of glioma sonicate by a Bradford protein assay program.

The µl

amounts of sonicate equaling 5, 10, and 25 µg protein for each cell line were then
incubated separately in 150 µl reactions with 0.2 pmol of radiolabelled 18 hp
MGMT substrate at 37°C for 2 hr. The labelled DNA substrate was then extracted
three

times

with

phenol/chloroform:isoamyl

alcohol

(24:1),

once

with

chloroform:isoamyl alcohol and then precipitated (-70°C, 1 hr) with 1/10 vol. 3M
sodium acetate pH 5.2, 3 vol 100% ethanol. After centrifugation (12,000 RPM, 30
min) the DNA was washed with 70% ethanol and lyophilized. The lyophilized DNA
was resuspended in 17 µl ddH 20 and incubated with 10 units of Pvull (BRL) for 1
hr at 37°C. Three unreacted control samples were incubated with no RE, Pvull, or
Haelll.

The digestion reactions were then terminated by adding 9 µl of 96%

formamide dye (96% formamide/lmM EDTA/0.1% BPB/0.1% xylene cyanol). After
a 5 min incubation at 95°C and a quick cooling on ice, 10 µl of each sample was
electrophoresed on a 20% denaturing polyacrylamide gel for 1.5 hr. The relative
amount of radiolabelled, cleaved to uncleaved DNA substrate was then determined
with

a

Betascope blot

analyzer.

Additionally, the gels were directly

autoradiographed for 2-3 hr.

DNA Isolation
Genomic DNA was isolated from 10 - 20 X 106 cells of each glioma cell line.
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The cells were centrifuged (2200 RPM, 5 min), washed twice with cold lX PBS pH
7.4, and lysed in cell lysis buffer [17 mM NaHCOi27.6 mM Na2C0 3/1 mM EDTA
pH 8.0/0.4% N-lauroylsarcosine/.024% proteinase K (Merck)].
incubation

at

37°C for

4 -

7 hr,

DNA was

recovered

Following
by

three

phenol/chloroform:isoamyl alcohol (24:1) extractions, one chloroform:isoamyl
alcohol extraction, and an ethanol precipitation (0.2 volumes 11 M ammonium
acetate/2.5 volumes 95% ethanol).

The DNA pellet was washed twice in 70%

ethanol, resuspended in 4 ml of ddH20, and treated with 40 µg of RNAse for 30 min
at 37°C. The extraction, precipitation and ethanol washing steps were repeated,
followed by DNA resuspension in 400-800 µl 10 mM Tris-HCl/1 mM EDTA, pH 8.0.

Analysis of the Methylation Status of the Body of the MGMT Gene
Analysis of the methylation status of the body of the MGMT gene in the
glioma cell lines was accomplished by Southern blot analysis of genomic DNA
digested with the methylation sensitive and insensitive isoschizomers Hpall and
Mspl, respectively (BRL).

Ten µg of genomic DNA from each cell line was

incubated (37°C, 6-8 h) in a 200 µl reaction containing lX RE buffer and Hpall (710 U/µg DNA) or Mspl (7-10 U/µg DNA). To control for completion of digestion,
aliquots (20 µl) of the final reaction mixture were removed from each digestion
reaction and incubated with a uniformly 32P-labelled MGMT cDNA. Generation of
the expected restriction fragment pattern of the labelled MGMT cDNA, as assessed
by autoradiography of these control samples following electrophoresis and transfer
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to a nylon membrane, reflected complete digestion in the primary digests. DNA
from the primary digests was then extracted, precipitated, and resuspended in 20
µl ddH 20. For analysis of intron 1 and the 3' end of the gene, the DNA samples

were further digested with EcoRI (10 U/ µg) for 6 hr. Equal amounts (10 µg) of
DNA from each digest were electrophoresed (15-20 V, 24 hr) through 0.7 % agarose
gels. The DNA was then depurinated by soaking the gel in 0.25 M HCl for 15 min.
After rinsing the gel in dH20, the DNA was denatured by soaking the gel in 0.5 M
NaOH/1.5 M NaCl for 30 min. Following a brief dH 20 rinse, the gel was submerged
in neutralization solution (0.5 M Tris pH 7.5/3 M NaCl) for 45 min. DNA was then
transferred from the gel to a nylon membrane by capillary blotting in lX SSC.
Following the transfer, the membrane was submerged in 0.4 N NaOH for 45 sec,
and then in 0.2 M Tris/2X SSC for 90 sec. After allowing the membrane to dry at
room temperature, the DNA was covalently bound to the membrane by UV
crosslinking (UV Stratalinker).

The membrane was prehybridized and then

hybridized to various MGMT intron specific probes in a manner analogous to that
described for northern blots.

Ouantitation of Methylation at an MGMT Intron 1 Site
The percent of MGMT gene alleles within each glioma cell line that are
methylated at an intron 1 site, located 5 kb 5' of the translation start site, was
determined by Southern blot analysis of EcoRI digested glioma cell line DNA
hybridized with the 3.8 kb EcoRI intron I probe described above. DNA (10 - 20 µg)

..,.
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from each glioma cell line was digested with 75 U EcoRI for 6 hr at 37°C and then
overnight with an additional 100 U EcoRI.

Relative hybridization of the

radiolabelled intron I fragment to the 3.8 kb (unmethylated) and 4.5 kb
(methylated) EcoRI digestion products was assessed with a Betascope 603 blot
analyzer. The percent methylation of the EcoRI site was calculated as the ratio of
4.5 kb fragments to 3.8

+ 4.5 kb fragments multiplied by 100. The relationship

between percent methylation and MGMT mRNA levels was examined by linear
regression analysis (SigmaPlot5).

linker-Mediated PCR Analysis CLMPCRl of MGMT Promoter Methylation
For methylation analysis by LMPCR, nuclei were isolated from the glioma cell
lines according to a method described by Wijnholds, et al., 1988. 1X107

-

1X108

glioma cells were washed with ice-cold lX PBS, centrifuged (2300 RPM, 5 min) and
resuspended in 5 ml ice-cold buffer A (0.3 M sucrose/60 mM KCl/15 mM NaCl/60
mM Tris-Cl pH 8.0/0.5 mM spermidine/0.15 mM spermine/2 mM EDTA). 5 ml
cold buffer A with 1% Nonidet P40 (NP-40, Sigma) was added and the samples were
incubated on ice for 5 min. The sample was centrifuged (lOOOXg, 5 min) and the
nuclei pellet was washed with 15 ml of cold buffer A. DNA was isolated from the
nuclei according to Saluz, et al., 1987 by resuspending the nuclei in 5 ml of buffer
B (150 mM NaCI/5 mM EDTA pH 7.8), adding 5 ml of room temperature buffer
C [20 mM Tris-Cl/20 mM NaCI/20 mM EDTA/1% SDS/600 µg/ml proteinase K
(Sigma)] and incubating the samples at 37°C for 3 hr. RNase was added (100
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µg/ml) and the samples were incubated at 37°C for 1 hr. DNA was extracted and
precipitated as described above and then cut with EcoR I (5 U/µg) to reduce
viscosity. Following extraction and precipitation, the DNA was dialyzed for 20 hr
in 3 changes (at 4 hr, 18 hr and 19 hr) of 4 L ddH 20.

Forty µg of DNA was

cleaved with genomic sequencing chemicals as described by Maxam and Gilbert,
1980. For sequencing of plasmid DNA, 1 µl of BamH I cut plasmid (containing the
1.2 kb MGMT promoter) was added to 40 µg of dialyzed, sheared salmon sperm
DNA.
The LMPCR protocol was based on the method described by Pfeifer, .rt_fil.,
1989 and consisted of extension, ligation and amplification steps. All DNA primers
for LMPCR were gel purified except an 11 nt linker primer (see below). For
extension reactions, a 15 µl reaction containing 5.0 µg of cleaved genomic DNA, 0.5
pmol

of

the

extension

primer

(for

promoter

region

I;

5'-

CGGGCCATITGGCAAACTAAG-3', corresponding to MGMT promoter nt 655-675,
for region II; 5'-AGGCACAGAGCCTCAGGCGGAAGCT-3', corresponding to nt 805823), and lX sequenase buffer [United States Biochemical (USB)] was incubated
at 95°C for 3 min, and then 60°C for 30 min. The reaction was cooled on ice and
7.5 µl of dNTP mix [final concentration in mix was 0.062 mM dGTP/0.188 mM 7deaza dGTP/0.2 mM each of dCTP, dATP, dTTP (Pharmacia)], 0.5 µl of 0.5 M
MgC12, 0.95 µl of 1 M dithiothreitol and 1.5 µl of a 1:4 dilution (in TE pH 8.0) of
Sequenase version 2.0 (USB) were added. Following primer extension (48°C, 15
min), the reactions were cooled on ice, 6 µl of cold 300 mM Tris, pH 7. 7 was added,
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and the Sequenase was heat inactivated (67°C, 15 min). The reaction was cooled
on ice. In ligation steps, a double stranded DNA linker (see below) was ligated to
the extension products by addition of 45 µl of a ligation mix (13.33 mM MgC12/30
mM DTT/1.66 mM ATP/83.3 µg BSA/100 pmoles linker DNA and 3 U/reaction T4
DNA ligase (Promega)) to each reaction.

After ligation (18°C, 12-16 hr) the

reaction was heated (70°C, 10 min) and then cooled on ice.

The DNA was

precipitated (along with 10 µg yeast tRNA), washed with 70% ethanol, lyophilized
and resuspended in 67 µl ddH20. The ligated DNA was then incubated in a 100 µl
reaction containing 10 µl of dNTP mix (0.067 mM dGTP/0.133 mM 7-deaza
dGTP/0.2 mM each of dATP, dCTP, dTTP), lX Stoffel fragment buffer, 2.5 mM
MgC12, 10 U Stoffel fragment ofTaq Polymerase (Perkin Elmer Cetus), and 10 pmol
each of the longer (25 mer) linker primer and a nested gene-specific primer (for
promoter region 1; 5'-AGGCACAGAGCCTCAGGCGGAAGCT-3', nt 674-698, for
promoter region 2; 5'-TGGGCATGCGCCGACCCGGTC-3', nt 841-861)(13) and
amplified by PCR (5 min, 95°C followed by 18 cycles of 95°C for 1 min, 66°C for 2
min and 76°C for 3 min with a 5 sec extension of the 76°C step after each cycle and
10 min at 76°C after cycle 18).
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P labelled PCR products were generated through

two additional PCR cycles with a second nested end-labelled primer (promoter
region I; 5'-AGGCACAGAGCCTCAGGCGGAAGCTGGGA-3', nt 674-702, promoter
region 2; 5'-TGGGCATGCGCCGACCCGGTCGGG-3', nt 841-864). Seven µl of a
mix containing lX Stoffel buffer, 2.5 mM MgC12, 0.1 U Stoffel fragment/µl and 4.0
pmol of the 32P labelled primer (see below) was added to the amplification reaction.
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Following two cycles of PCR (same parameters as above except annealing was at
67°C and extension at 77°C), the DNA was extracted, precipitated, and resuspended
in 10 µl of LMPCR dye (80% formamide/45 mM Tris base/45 mM boric acid/1 mM
EDTA/.05% BPB/.05% xylene cyanol). Five µl of the sample was electrophoresed
(55 Watts, 2 • 3 hr) through a 6 % denaturing polyacrylamide gel. Radiolabelled
amplification products were detected by autoradiography (6-18 hr exposure).

In Vivo Dimethylsulfate CDMSl Footprint Analysis of the MGMT Promoter
Glioma cells were treated with 0.1 % DMS in fresh media (37°C, 2 min) and
then washed three times with lX PBS. DNA was then isolated, resuspended in lM
piperidine and heated for 30 min at 95°C. Following precipitation, the DNA was
washed twice with 80 % ethanol and lyophilized overnight. The DNA was
resuspended in ddH 20 and 5 µg was analyzed by linker-mediated PCR as described.

Gel Purification and Radiolabelin& of LMPCR Primers
DNA Primers were gel purified according to published protocols (Ausubel, fil.
al., 1992). 100-120 µg of each primer was diluted 2-fold in 2X formamide loading
buffer [lX TBE (lX TBE

= 89

mM Boric Acid/89 mM Tris base • 2.0mM

EDTA)/90% deionized formamide/0.5% BPB], heated to 95°C for 5 min and placed
on ice.

The entire sample (80 - 120 µl) was loaded on a 15 % denaturing

polyacrylamide gel using lX TBE for running buffer.

The samples were

electrophoresed (300-500 V, 2-3 hr) after which the gel was removed from the
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apparatus and wrapped in saran wrap.

The gel was placed over a thin-layer

chromatography plate with flourescent indicator and the DNA was visualized with
a U.V. lamp (U.V. shadowing). A gel slice containing the appropriately sized primer
DNA was removed, crushed, and the DNA was eluted (37°C, overnight, shaking
incubator) from the acrylamide in 0.3 M sodium acetate, pH 7.5. The primer DNA
was extracted once with phenol and once with chloroform before ethanol
precipitation. The primers were end-labelled in a reaction containing 25 - 35 pmol
primer (1 pmol/µl), 300 - 500 µCi gamma- 32P-ATP ( > 5000 Ci/mmol), lX T4
polynucleotide kinase buffer (Promega) and 0.05 U polynucleotide kinase/µl. The
reaction was incubated for 30 - 60 min at 37°C, 2 min at 95°C and cooled on ice.
Unincorporated gamma-32P-ATP was removed from the reaction by centrifugation
(4 min, 3800RPM) through a G-25 sephadex column (5 Prime - 3 Prime)
equilibrated with 3 ml of ddH 20.

Linker Annealine
The linker primer sequences and annealing reactions were as described by
Mueller

and

Wold,

1989.

The

25

nt

linker

primer

was

5'

GCGGTGACCCGGGAGATCTGAATTC - 3' and the 11 nt linker primer was 5' GAATTCAGATC - 3'. The primers were annealed in a 300 µl reaction containing
6000 pmoles of each primer and 250 mM Tris-Cl pH 7. 7. The reaction was heated
to 95°C for 5 min, centrifuged briefly and incubated at 70°C for 10 min. The
reaction was cooled to 25°C over 2 hr (2°C decrease every 5 min) and incubated at
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25°C for 1 hr. After cooling to 4°C (2°C decrease every 5.5 min), the reaction was
incubated at 4°C for 12 hr and stored at -20°C.

Analysis of Restriction Enzyme Accessibility to the MGMT Gene within Nuclei
Glioma cells were washed twice with cold lX PBS and harvested by scraping
into Sml of fresh lX PBS. The cells were centrifuged (5 min, 3500 RPM) and then
resuspended in 1.0 ml of cold RSB buffer (10 mM Tris,pH 8.0/10 mM NaCl/3 mM
MgC12) and .05 % NP-40 to disrupt the cell membranes. Nuclei were pelleted by
centrifugation (12,000RPM, 4 sec), washed twice in lX RE buffer and resuspended
in 350 µl fresh lX RE buffer. Nuclei equivalent to 30 µg of DNA were incubated (10
min, 37°C) with either Mspl (20 - 400 U), Avail (16 U), Alul (6 - 40 U), or DNAsel
(0.6 - 60 U). DNA was then isolated from the nuclei, precipitated, and resuspended
in ddH20 (1.0 µg DNA/µ1). For the promoter studies, 5.0 µg of DNA from the
nuclei digests was analyzed by LMPCR as described above, except autoradiograph
exposures were 2-5 hr, with intensifying screens. For analysis of RE accessibility to
the body of the gene, DNA was isolated from the nuclei, precipitated, and
resuspended in 16 µl dH20 + 2 µl lOX EcoR I buffer. All DNA samples were
digested with 100 U EcoRI (2 hr, 37°C), one sample with EcoRI and Mspl, (10
U/µg) and one with EcoRI and Hpall (10 U/µg). 10 µg of each digest was then
analyzed by Southern blot as described above.
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Gel Shift
To prepare protein extract for gel shift analysis 5 - 10Xl06 cells (glioma cells
and for control reactions, HeLa cells) were centrifuged (12,000 RPM, 5 sec), the
supernatant was discarded and the cells were quickly frozen in liquid nitrogen. The
cells were resuspended in 5 volumes buffer C (25 % glycerol/420 mM NaCI/1.5 mM
MgC12/0.2 mM EDTA/up to 100 ml with ddH20/20 mM Hepes pH 7.9/0.5 mM
DTT/0.5 mM PMSF), centrifuged (100,000xg, 5 min), and the supernatant pipetted
into a new tube. Ten µg cell extract (measured spectrophotometrically, as described
for MGMT assay) was incubated with 0.1 ng (1 ng/µg) of a double stranded,
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P-

end-labelled, 22 hp DNA fragment (10,000 - 50,000 CPM/µl containing a single Spl
binding site (Spl oligonucleotide, Promega) in a 25 µl reaction containing 1.0 µl
poly(dl)poly(dC)(0.5 µg/µl), 1.0 µl of BSA (10 mg/ml), and lX binding buffer (lX

= 10 mM Tris pH 7.5/50 mM NaCl/1 mM EDTA/5% glycerol/1 mM DTT).

For

the

Spl

specific competition experiment, an

100-fold excess

unlabelled

oligonucleotide was added 20 min prior to addition of HeLa cell extract. A 100-fold
excess unlabelled heat shock factor oligonucleotide (non-specific competitor)(5'CTAGAAGCTTCTAGAAGCTTCTAG-3') was added to a separate tube prior to
addition of HeLa cell protein extract. Each reaction (HeLa controls and glioma
samples) was incubated for 20 min at 25°C, 2.5 µl dye (50 % glycerol - 0.2 % BPB 0.2 % xylene cyanol) was added and the sample was electrophoresed (120 - 160 V,
2 - 3 hr) through a 4 % polyacrylamide gel. The gel was autoradiographed for 1 -

5 hr.

CHAPTER IV
RESULTS

Analysis of the MGMT Gene Codina= Sequences
To examine the organization of the human MGMT gene coding sequences, a
genomic library was screened with an MGMT cDNA probe. Twenty positive clones
isolated after primary screening were purified to homogeneity through secondary
and tertiary screening.

The primary, secondary and tertiary screenings of a

representative clone (7c) are shown in fig. 1. The clones were divided into four
groups based on hybridization to one of four cDNA restriction fragment probes
(fig.2). Two MGMT genomic clones (lb/2e) hybridized to cDNA fragments 3 and
4, suggesting that these clones may contain two or more exons, one common to
group 3 clones and one common to group 4. Each clone was analysed for BamHI,
Hindlll, and EcoRI restriction sites, and then aligned with the other clones. Eight
of these clones with minimal overlap were used to generate a preliminary map of
the coding sequences of the MGMT gene consisting of four translated exons and
spanning > 80 kb (fig.3) (exon 1, not shown here, is nontranslated (Harris, et al.,
1991). Comparison of the nucleotide sequence of the S' most exon, derived from
sequencing genomic subclone pS'BH (fig.3), to the published cDNA sequences (Tano,

.ru.i., 1990) demonstrated that the 135 bp comprising this exon was contiguous with
44
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Figure 1. Primary, secondary and tertiary screening of a human genomic library
with a radiolabeled MGMT cDNA. Approximately 1X106 clones were tested for
hybridization to the 730 hp MGMT cDNA probe (which includes all the protein
coding portions). Tuenty positive clones were identified by the presence and
identical location of positive signal on duplicate filters (from the same LB plate).
A LB plug containing each of these clones corresponding to a positive signal (eg.
arrow in 1° panel) was removed from the plate, eluted in 1 M SM buffer, and then
purified through secondary (2°) and tertiary (3°) screening. Every phage plaque
present on the tertiary screening plates hybridized to the MGMT cDNA probe,
indicating that these phage populations contained MGMT gene fragments and were
purified to homogeneity.
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Figure 2 Relative placement of genomic clones into one of four groups based on
hybridization to MGMT cDNA fragment probes. Tuo µg of each genomic clone
were cleaved with Notl (10 U for 1 hr) and analyzed by Southern blot, as described,
with sequential hybridization to each of the four cDNA fragment probes (open bars
with vertical lines). Positive hybridization to genomic clones 2e and lb was seen
with the two 3' probes.
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Figure 3. Restriction enzyme map of the coding sequences of the human MGMT
gene. A genomic library derived from a human fibroblast cell line DNA was
screened with a 32P-labelled MGMT cDNA that spanned nucleotides 70-777 (which
includes the entire protein coding region). Eight positive clones analyzed by
restriction enzyme mapping with BamHl(B), EcoRl(E), and Hindlll(H), were
aligned to form a discontinuous map of the gene. Exons (open triangles) within two
genomic subclones, p5'BH and p7cNN, were sequenced and compared to the
corresponding cDNA nucleotides. Nucleotides complementary to cDNA sequences
590-776 were identified within genomic clone llb (exon 5) by PCR amplification
with primers defining this cDNA region. Gaps in the map represent intron regions
of unknown size. The positions and length of the intron probes used for
methylation analysis are indicated by solid lines located below the subclones. The
dashed line immediately 5' of the intron 3 probe indicates the position of a 4. 7 kb
EcoRI probe also used to examine methylation.
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exon 1 in the MGMT cDNA. This region was therefore designated exon 2. Exon 2
contains approximately 12 nontranslated nucleotides followed by the translation
start site and nucleotides encoding amino acids 1 through 41. Exon 3 encodes >
41 amino acids, beginning with amino acid 42, and is followed by two 3' exons which
were separated by an intron of less than 7 kb. The first of these two exons (exon
4) was identified by hybridization of a 3' MGMT cDNA fragment to genomic clone
Sb DNA. The 3'-most exon (exon 5), analysed by PCR amplification of genomic
clone llb DNA with 3' MGMT cDNA specific primers, spans > 185 hp and extends
into the 3' nontranslated region. These genomic clones include all translated exons
and span the body of the MGMT gene (Nakatsu, et al., 1993).

Map_pina= of CpG Island Sensitive RE Sites within MGMT Genomic Clones

Because the MGMT cDNA is very GC rich and contains and overabundance
of CpGs, it is possible that one or more of the exons which comprise the cDNA
sequence may be part of a CpG island. In order to identify potential CpG islands
within the MGMT gene, the sites for CpG island-sensitive RE were mapped within
genomic clones from each MGMT gene region. The recognition sites for CpG island
sensitive RE are entirely composed of cytosines and guanines and contain one or
more CpG dinucleotide. These sites are therefore rare in bulk DNA, but occur
relatively frequently in CpG island DNA (Lindsay and Bird, 1987). Clusters of
three or more of these sites within 0.5 - 3.0 kb indicate the location of potential
CpG islands. MGMT genomic clones from each of the four groups were analyzed
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Figure 4. Map of sites for CpG island-sensitive RE in genomic clone 7c. The
position of sites for BssHII (B), Eagl (E), Nael (N), Notl (Nt) Saeli (Sc) and Smal
(S) were determined within clone 7c DNA by RE mapping. Subclones containing
each of the three clusters of the CpG island-sensitive RE sites are shown directly
below the region of 7c from which they were derived. Ee, EcoRI site, and (open
triangles), position of exon 3. Sequence data from each of the subcloned regions is
shown in table 1.
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for potential CpG islands by mapping the restriction sites for the CpG islandsensitive REs BssHII, Eagl, Nari, Nael, Notl, Smal, and Sacll. Although most of
the MGMT genomic clones contained only a few of these sites and generally not in
clusters, three obvious clusters of these sites were found within genomic clone 7c
(fig. 4). The 5' most cluster was associated with exon III and the middle and 3'
clusters are contained in intron 3.

DNA containing each cluster of sites was

subcloned and partially sequenced to determine if these regions have the high GC
content ( > 50%) and overabundance of the dinucleotide CpG [a ratio > 0.6,
calculated from the equation ((#CpG/#G x #C) x #nucleotides analyzed)]
characteristic of CpG islands (Gardiner-Garden and Frommer, 1987). The results
of the sequence analysis are shown in table 1. All three regions analyzed did have
an overabundance of CpGs relative to bulk DNA and a GC content between 40-60%
The overabundance of CpGs however, was clearly below the frequency found in CpG
islands. Analysis of these sequences in segments of 125 - 565 nt, rather than as a
whole, revealed small but CpG-rich regions of the MGMT gene. The significance
of small CpG-rich segments of DNA is unknown, but because of the high content
of CpGs the methylation status of these regions may be relevant in a potentially
methylation-mediated establishment or maintenance of glioma MGMT gene
expression.

Analysis of MGMT Expression in 10 Human Glioma Cell Lines
MGMT expression in each glioma cell line was determined at the mRNA and
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Table 1. Analysis of GC content and CpG ratios in regions cf the
MGMT gene that contain a cluster of recognition sites for CpG island
sensitive restriction enzymes
I

DNA Region

I

:I Nucleotides
! Analyzed

%GC

I
I
I

CpG island DNA

500-2000

>50%

>0.60

Region 1- exon 3
1.6kb Eag-Nae

1600
(1-1600)

54.0%

0.41

565
(1035-1600)

57.2

0.53

.

536
(5' 1-536)

50.7%

0.35

Region 2- intron 3
4.7kb Eco-Eco

160
(5' 1-160)

58.0

0.48

53.0%

0.32

150
(3' 1-150)

58.4

0.53

880
(5' 1-180)

43.0%

0.30

490
(5' 390-880)

49.3

0.45

765
(3' 1-765)

53.9%

0.29

150
(3' 1-150)

63.0%

0.46

994 ;~;
(3 '1-994)

Region 3- intron 3
3.8kb Eco-Eco

I

! CpG ratio•

Bulk DNA

I

-

~~,:~

II

<40.0%

I
=l

0.20

I

• CpG ratio calculated from the equation: LpU ratio
#LpU dmucleotJ des/ (#C X
#G)] X # nucleotides analyzed.
Note: Region 2 and 3 were sequenced inward from both ends of the subclones. In the
Nucleotides Analyzed column the sequences are therefore denoted as 5' or 3' with respect .
to their ends within the MGMT gene.
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Figure 5. Northern blot analysis of MGMT mRNA levels in 10 glioma cell lines.
Twenty µg of total cellular RNA from MGMT+ and MGMT- glioma cell lines was
denatured, electrophoresed, transferred to a nylon membrane and hybridized with
a 32P-labelled MGMT cDNA (top panel). Following MGMT probe removal, the
membrane was hybridized with a histone H3.3 cDNA probe (bottom panel). The
membranes were washed under stringent conditions (60°C, 7 min, 0.1 % SDS/O.lX
SSPE in a circulating water bath) and exposed to x-ray film (4-7 days) in the
presence of intensifying screens.
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protein levels.
The relative amount of MGMT mRNA in each glioma cell line was measured
by northern blot analysis with an MGMT cDNA probe.

The results of a

representative northern blot, seen in figure 5, demonstrated that MGMT mRNA was
present in 1'98, U138, SF763, SF767, NAT, U373, and HS683 but was not detectable
in Al235, CLA, or CRO (top panel). The amount of MGMT mRNA within each cell
line was quantitated and then expressed as the average of two independent northern
blots (Table 2). In order to ensure that the lack of detectable MGMT mRNA in
Al235, CLA and CRO was not simply due to degraded RNA in these samples, the
northern blots were rehybridized with the cDNA complementary to the histone H3.3
gene. Histone H3.3 mRNA should be present in all the cell lines as histone H3.3
gene expression is constituitive and cell cycle independent (Wellman, et al., 1987).
Figure 5 (bottom panel) shows that histone H3.3 mRNA was present in the RNA
from all the cell lines indicating that the lack of detectable MGMT mRNA in A1235,
CLA, and CRO was not due to degraded RNA in these samples.
The relative levels of MGMT activity were determined from an in vitro assay
that measures the ability of glioma protein extracts to remove a methyl-group
adduct from the 0-6 position of guanine in an 18 hp DNA substrate (Wu, et al.,
1987; Futscher, et al., 1989). Five, ten, or twenty-five µg of protein (lanes 1,2,3 of
each triplet, respectively) from glioma cell sonicates were incubated with a
radiolabelled 18 bp DNA fragment that contains a methyl group adduct at 0 6guanine within a Pvull RE site (CAGCTGme). The amount of MGMT activity in
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Figure 6. In vitro assay of MGMT activity within each glioma cell line. Five, ten or
twenty-five µg of glioma cell sonicates were incubated (2 hr, 37°C) with a
radiolabelled 18 hp DNA substrate containing a methyl-group adduct at the 0-6
position of guanine within a Pvull recognition site. Unreacted 18 hp probe was
incubated with Pvull (P), Haelll (H) or no enzyme (C). The DNA from control and
glioma cell sonicate-reacted samples was extracted, precipitated, and resuspended
in lX Pvull buffer (except the Haelll control sample (H) which was resuspended
in lX Haelll buffer). The DNA was digested with Pvull (1 hr, 37°C), 9 µI of 95%
formamide dye was added and one third of the reaction was electrophoresed (1 - 2
hr, 26 mA) through a 20% denaturing polyacrylamide gel. The gel was
autoradiographed for 1 - 3 hr in the presence of intensifying screens.
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Table 2. Quantitation of MGMT mRNA and MGMT activity in
ten glioma cell lines

Glioma Cell
Line

MGMT
mRNA levels
(% of T98)

MGMT
Activity
(%of T98)

T-98

100%

100%

SF-763

78.8

121 + 15

U-138

76.8

96 + 12

SF-767

61.6

110 + 19

Nat

48.5

79 + 12

U-373

38.4

38 + 2

HS-683

33.3

38 + 9

A1235

0

<1

Cla

0

<1

Cro

0

<1

Table 2. Quantitation of MGMT mRNA and MGMT activity in ten glioma cell lines.
3
MGMT mRNA levels in each cell line were quantitated (Betascope 603 blot
analyzer) from two independent northern blots, averaged, and expressed as the
percent of '1'98 MGMT mRNA level. Within each cell line the average difference
between duplicate experiments was < 12%. bValues for MGMT activity, determined
by an in vitro assay that measured the ability of glioma cell sonicates to remove a
methyl group adduct from the 0 6-position of guanine in a 32P-labelled 18 bp DNA
substrate, are the mean ..±. S.D. of three independent experiments expressed as
percent of '1'98 MGMT activity.
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glioma cell sonicates is thus proportional to the relative levels of repaired 18 bp
DNA substrate following incubation of the 06-methylated 18 bp DNA with glioma cell
sonicates. After incubation, the methyl-adducted and repaired 18 bp DNA were
distinguished by digestion with Pvull. (Pvull is sensitive to methyl adducts at 0 6guanine and therefore does not cut the adducted 18 bp DNA). The products of
Pvull digestion of the repaired 18 bp DNA were radiolabelled 8 bp and unlabelled
10 bp DNA. The 8 bp and 10 bp DNA were size separated from the adducted (and
therefore uncleaved) 18 bp DNA by electrophoresis through a 20 % denaturing
polyacrylamide gel.

The gel was autoradiographed directly to detect the

radiolabelled 8 nt and 18 nt DNA. The relative proportion of 8 bp to 18 bp DNA
following incubation of the 0 6-methylguanine-containing 18 bp DNA with glioma
cell sonicates is thus directly related to the amount of MGMT activity within the
cell sonicate.
Figure 6 shows an MGMT assay of glioma cell sonicates. There was no
detectable cleavage of the unreacted probe with (P) or without (C) Pvull digestion,
indicating that prior to incubation with glioma cell extracts the probe was fully
methylated at the 0 6-position of guanine. Substantial (70-90%) digestion of the
probe to a 12 bp fragment by Haelll (H) indicated that the probe DNA was not
inherently resistant to RE digestion. MGMT activity increased in a linear fashion
with increasing amounts of protein added. Quantitation of MGMT activity in each
cell line, expressed as a mean+/- standard deviation from three independent assay
samples, is shown in table 2. The rank order of the MGMT expressing glioma cell
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lines according to MGMT activity, from highest to lowest, was SF763, SF767, T98,
U138, NAT, HS683, and U373. MGMT activity is undetectable, in this assay system,
in glioma cell lines A1235, CLA and CRO, consistent with the lack of detectable
MGMT mRNA in these cell lines.

Differences in the rank order of cell lines

according to MGMT mRNA versus MGMT activity may reflect small differences in
post-transcriptional events such as mRNA stability, translation efficiency or protein
half-life.

Analysis of MGMT Gene Arraneement
The absence of MGMT expression in CLA, CRO, and A1235 could result from
a deletion or rearrangement of the MGMT gene as gliomas frequently lose one copy
of chromosome 10 (Collins and James, 1993) and/or have deletions of lOq
(Karlbom, et al., 1993), the location of the MGMT gene (Natarajan, et al., 1992).
The structure of the MGMT gene was therefore assessed in each glioma cell line
by Southern blot analysis. Figure 7A and 78 represent Southern blots of Mspl and
EcoRI digested DNA, respectively, hybridized with a radiolabelled MGMT cDNA.
The identity of hybridization patterns across all cell lines in each blot (except SF763
in the Msp blot) indicates that the lack of MGMT expression in the 3 MGMT- cell
lines was not a result of deletion or gross rearrangement of the MGMT gene. The
additional MGMT cDNA-recognized Msp fragment in the MGMT+ cell line SF763
is likely unrelated to (or not required for) MGMT expression as it is not detected
in any of the other MGMT+ cell lines. The lack of MGMT mRNA and MGMT
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Figure 7. Southern blot analysis of MGMT gene structure in glioma cells. Ten µg
of DNA from each glioma cell line was digested with Mspl (10 U/ µg DNA) or EcoRI
(10 U/ µg DNA). The DNA was extracted, precipitated and resuspended in ddH 20
and loading dye. The DNA was electrophoresed through a 1% agarose gel,
transferred to a nylon membrane and hybridized to a 730 hp radiolabelled MGMT
cDNA probe. The membranes were washed under stringent conditions (as des.cribed
in fig.5), dried and autoradiographed for 2 - 4 days in the presence of intensifying
screens.
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activity, despite the presence of an intact MGMT gene suggests that the MGMT
gene is regulated at the transcriptional level. The possibility that point mutations
or very small deletions inactivate the MGMT gene cannot be excluded, but is
considered unlikely, as the low frequency of point mutations in genes is incongruous
with the high incidence of MGMT- cell lines (20 - 30%). Recent studies have
suggested that other mechanisms of gene inactivation, such as changes in cytosine
methylation, which occur frequently in tumor cells (Goelz and Vogelstein, 19S5; De
Bustros, et al., 19SS), may influence MGMT gene expression (Pieper, et al., 1991).

Quantitative Analysis of MGMT Gene Methylation in Glioma Cell Lines
In order to examine the relationship between methylation and MGMT
expression in a quantitative fashion, the percent of MGMT gene alleles that were
methylated at an MGMT intron I site, 5kb upstream of the translation start site (*
in fig. 3), within each glioma cell line was determined by Southern blot analysis with
EcoRI digested glioma DNA (fig. SA) and then compared to MGMT mRNA levels
by linear regression analysis (fig.SB). As a result of the methylation sensitivity of
EcoRI (EcoRI will not cleave at its recognition site, GAATTC, if the cytosine is
followed

by a

guanine and

the cytosine of this

CG

dinucleotide is

methylated)(Nelson, .fil.Jtl., 19S9), when the 3' EcoRI site flanking the 3.S kb EcoRI
intron 1 segment of the MGMT gene (see tig.3) was methylated in glioma DNA, the
DNA was cut at the next available EcoRI site, approximately 0.7 kb downstream,
generating a larger, 4.5 kb fragment. The proportion of 4.5 kb to 4.5 kb

+ 3.S kb
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fragments in the DNA of each cell line was therefore a measure of the percent of
methylated (at this site) MGMT gene alleles within a population of glioma cells.
In figure SA, the cell lines are arranged from left to right in order of decreasing
MGMT expression. The results of this analysis demonstrate that methylation was
graded across the cell lines at the intron 1 EcoRI site and increased with increasing
MGMT expression (fig.S). The methylation status of this intron 1 site correlates
(r= O.S57, p < .001, fig.SB) with MGMT mRNA levels in a similar, positive fashion
as previously seen in MGMT exons (Pieper, et al., 1991). The two minimally
MGMT+ cell lines had methylation levels similar to those in MGMT- cell lines.
The percent methylation at this site within each cell line varied on average less than
20 percent between two experiments

(which were done four months apart)

indicating that the partial methylation status of this site within each cell line may
be stable over time.

Analysis of the Methylation Status of Introns of the MGMT Gene
To determine if the graded relationship between methylation and MGMT
expression noted at the intron 1 site (and previously in exons) is present in a
uniform fashion across the body of the MGMT gene, the methylation status of
intron regions, 4-10 kb distant from the nearest exons and >25 kb distant from
each other, across the body of the gene was examined in the glioma cells lines.
Southern blots ofMspl (methylation insensitive) and Hpall (methylation sensitive)
digested glioma DNA were hybridized separately with 3 intron probes. The probes
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Figure 9. Southern blot analysis ofMspl/Hpall site (CCGG) methylation in MGMT
intron 1. DNA from MGMT expressing (MGMT+) and nonexpressing (MGMT-)
glioma cell lines was digested with either A) Mspl (7-10 U/µg DNA) or B) Hpall
(7-10 U/µg DNA), followed by digestion with EcoRI (10 U/µg DNA). Following
electrophoresis through a 1.0% agarose gel and transfer to a nylon membrane the
DNA (10 µg/sample), arranged from left to right in order of decreasing MGMT
expression in the cell line of origin, was hybridized with a 32P-labelled 3.8 kb
MGMT intron 1 fragment derived from genomic clone ld and located 5 kb 5' of
exon 2 (see fig.3). Hybridized membranes were washed under stringent conditions
(as described in fig.5) and then autoradiographed (4 days) in the presence of
intensifying screens.
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were derived from 5', middle, and 3' intron regions of the MGMT gene. The
locations of each intron segment within the MGMT gene are depicted in fig. 3.
Southern blot analysis of the methylation status of a 3.8 kb MGMT intron 1
region, located approximately 5 kb 5' of exon 1 and 45 kb 3' of the MGMT
promoter (see fig.3, intron probes), in the glioma cell lines is shown in figure 9. The
pattern of intron 1 probe-hybridization to Mspl digested DNA from the glioma cell
lines (fig.9A) was the same in all lanes (with the exception the MGMT gene in CRO,
lane 7, which has a point mutation or very small deletion in all alleles)), indicating
that the 3.8 kb intron 1 region was identical, with respect to the number and
location of Mspl/Hpall sites. Southern blot analysis of Hpall digested DNA from
glioma cell lines (fig.9B), arranged from left to right in order of decreasing MGMT
expression, indicates that the intron 1 segment of the MGMT gene was relatively
unmethylated (lower molecular weight, greater degree of Hpall digestion) in the
minimally MGMT+

and MGMT- cell lines and methylated (higher molecular

weight, less Hpall digestion) in the MGMT+ cell lines, consistent with the
quantitative analysis of methylation of the EcoRI CpG bordering this region.
Additionally, the similarity in percent methylation of the intron 1 EcoRI site in
HS683 and U373 (both minimally MGMT+ cell lines) compared to MGMT- cell
lines was also detected in the extent of Hpall site methylation in intron 1 (fig.9B).
The presence of both the methylated and unmethylated fragments in Hpall digested
DNA from the MGMT+ glioma cell lines (fig. 9B, lanes 1-4) suggests the existence
of allelic differences (within a single cell) and/or population differences (within
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Figure 10. Analysis of the extent of Mspl and Hpall digestion of the samples
described in fig.9. Aliquots (20 µl) of each digestion reaction were removed from
the primary digests (Mspl and Hpall digests, fig.9) and incubated with a uniformly
32
P-labelled MGMT cDNA. The samples were electrophoresed through a 1.5 %
agarose gel, transferred to a nylon membrane and autoradiographed (1 - 4-hr) in
the presence of intensifying screens.
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Figure 11. Southern blot analysis of Mspl/Hpall site methylation in MGMT intron
3. A) Mspl and B) Hpall digested DNA from each glioma cell line was analyzed
by Southern blot analysis as described in fig.9 except that hybridization was with
a 32P-labelled MGMT intron 3 fragment derived from genomic clone 7c and located
10 kb 3' of exon III (see fig.3). Complete digestion of all samples was determined
as described in fig.10.
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each cell line) in MGMT gene methylation patterns. The variable hybridization
intensities within each lane and across lanes likely reflect the degree of
heterogeneity in methylation at various MGMT intron sites, i.e., a greater degree of
heterogeneity in MGMT gene methylation within a cell line results in fewer copies
of a given Hpall fragment and thus weaker hybridization signal for that fragment.
To exclude the possibility that the differences in the extent of Hpall digestion of the
MGMT gene from each glioma cell line might be due to incomplete Hpall digestion,
rather than methylation differences, control digests were performed. Incubation of
20 µl of each primary Hpall digest (as well as Mspl digests) with a uniformly 32Plabelled MGMT cDNA, followed by electrophoresis and autoradiography, resulted
in an identical digestion pattern in all the samples (fig.10). This suggests that the
digestion was complete in the primary Hpall and Mspl digests, and the differences
in extent of digestion in the primary samples can be attributed to methylation.
Control digests were performed for each independent experiment.
Southern blot analysis of the methylation status of a 3.8 kb intron 3 region,
10 kb 3' of exon 3 (see fig.3, intron probes) is shown in figure 11. Analysis of Mspl
digested glioma DNA indicated that the number and position of Mspl/Hpall sites
in this intron 3 region was the same in all cell lines, regardless of MGMT
expression (fig.HA). Figure 118 demonstrates that Hpall sites throughout this
intron 3 region (6 kb through 14 kb 3' of exon 3) were methylated in MGMT+
glioma cell lines and relatively unmethylated in minimally MGMT+ and MGMTglioma cell lines. The presence of a 1.1 kb fragment in all lanes (fig.118) indicates
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Figure 12. Southern blot analysis of Mspl/Hpall site methylation in the 3' end of
the MGMT gene. A) Mspl and B) Hpall digested DNA samples from each glioma
cell line were analyzed by Southern blot analysis as described in fig.9 except
hybridization was with a 32P-labelled 3.5 kb Eagl fragment derived from genomic
clone llb and located 4 kb 3' of exon 5. Complete digestion of all samples was
determined as described in fig. 10.
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Figure 13. Southern blot analysis of Mspl/Hpall site methylation in normal human
T lymphocytes (T cells) and brain, and in a brain tumor sample (GBM). Mspl
(lanes 1 - 4) and Hpall (lanes S - 8) digested DNA from the human normal and
tumor cells was analyzed by Southern blot analysis as described in fig.9 (including
use of the same intron 1 probe).
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that the two Hpall sites flanking this fragment were unmethylated to an extent,
estimated by hybridization intensity, in all cell lines, with the greater number of
unmethylated alleles in the MGMT- cell lines (fig. llB). The strong hybridization
to high molecular weight Hpall fragments from MGMT+ cell lines (fig.11, lanes 14) indicates that in a large number of these cells all Hpall sites were methylated
over 7-12 kb of intron 3.
Analysis of methylation in the 3' end of the MGMT gene, shown in fig.12
yielded results similar to those in intron 1, intron 3 and exons, i.e. the MGMT gene
was methylated in MGMT+ cell lines and relatively unmethylated in minimally
MGMT+ and MGMT- cell lines. These results suggest that, within each cell line,
the methylation status of the MGMT gene is uniform over >80 kb defined by the
probes used and correlates in a positive, graded fashion with MGMT expression.
The body of the MGMT gene was also heavily methylated in several
noncultured human cells that express the MGMT gene. Figure 13 shows a Southern
blot analysis of Mspl/EcoRI (lanes 1-4) and Hpall/EcoRI (lanes 5-8) cut DNA
from a normal human brain sample, a glioblastoma multiforme tumor sample
(GBM), and T lymphocytes, hybridized with the MGMT intron 1 probe. The
number and position of Mspl sites in this region was the same in T cells and
normal brain, but an additional band of 2.4 kb was present only in the tumor
sample. The 2.4 kb band corresponds exactly to the Mspl fragment seen in the
intron I from CLA cells (fig.9A) and may therefore be derived from a point
mutation, common to CLA cells and >50 % of the cells in the tumor sample, that
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destroys an Mspl site flanking the 2.0 kb Msp I fragment. The MGMT gene was
methylated at virtually all the Hpall sites in intron 1 of T lymphocytes, which have
relatively high levels of MGMT activity (approximately 3-4 times the level in the
T98 cell line). The MGMT gene in the tumor and normal human brain samples
was also methylated to a level similar to the MGMT+ glioma cell lines, which
express similar levels of MGMT, but to a lesser extent than in T lymphocytes. The
somewhat decreased level of methylation in the brain sample compared to the tumor
was consistent with the slightly lower level of MGMT activity in the brain sample.
The apparent heterogeneity of MGMT methylation in the normal brain sample
might be explained by differences in MGMT gene methylation patterns in the
different cell types present in this sample.

RE Accessibility to the Body of the MGMT Gene within Intact Nuclei
The observation that methylation of the body of the MGMT gene correlated
in a direct, graded fashion with MGMT expression suggested that there may be
methylation related differences in chromatin structure of the body of the gene. The
chromatin structure of the body of the MGMT gene was examined by determining
the relative accessibility of Mspl, Alul, and DNasel to the body of the MGMT gene
within isolated nuclei from MGMT+ and MGMT- glioma cells. Since both histones
and methylated DNA binding proteins (MeCps) block RE digestion in nuclei (Tazi
and Bird, 1990; Antequera, et al., 1989) ), this analysis assesses, at least, the
combined effect of these proteins on chromatin structure.
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Figure 14. Southern blot analysis of Mspl accessibility to and methylation of an
MGMT intron 1 region. For analysis of Mspl accessibility to the MGMT gene,
nuclei from MGMT+ (SF767) and MGMT- (CLA) glioma cells were incubated with
Mspl (lanes 1,6; 20 U Mspl for 10 min, lanes 2,7; 150 U Mspl for 2 hr), the DNA
was isolated and further cleaved with EcoRI. For analysis of intron 1 methylation,
DNA was also isolated from untreated nuclei and digested with Mspl/EcoRI (lanes
3,8), Hpall/EcoRI (lanes 4,9) or EcoRI only (lanes 5,10). The DNA from all the
samples was analyzed by Southern blot as described in fig.9 (including use of the
same intron 1 probe).
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Figure 15. Southern blot analysis of Mspl accessibility to and methylation of an
MGMT intron 1 region in MGMT+ (1'98) and MGMT- (A1235) glioma cells.
Analysis ofMspl accessibility to the MGMT intron 1 region within intact nuclei and
methylation analysis of naked DNA were performed exactly as described in fig.14.
Lanes 1,6; nuclei incubated with 20 U Mspl for 10 min, lanes 2,7; nuclei incubated
with 150 U Mspl for 2 hr, lanes 3,8; Mspl/EcoRI cut naked DNA, lanes 4,9;
Hpall/EcoRI cut naked DNA, lanes 5,10; EcoRI cut naked DNA.
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Figure 16. Southern blot analysis of Mspl accessibility to and methylation of an
MGMT intron 1 region in MGMT+ (T98) and MGMT- (Colo) cells. Analysis of
Mspl accessibility to the MGMT intron 1 region within intact nuclei and
methylation analysis of naked DNA were performed exactly as described in fig.14.
Lanes 1,6; nuclei incubated with 20 U Mspl for 10 min, lanes 2,7; nuclei incubated
with 150 U Mspl for 2 hr, lanes 3,8; Mspl/EcoRI cut naked DNA, lanes 4,9;
Hpall/EcoRI cut naked DNA, lanes 5,10; EcoRI cut naked DNA.
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The recognition site for Mspl (CCGG) contains a CpG and Mspl
accessibility to DNA in nuclei may therefore be directly influenced by MeCps
(Antequera, et al., 1989). Comparison of the relative accessibility of Mspl to
MGMT gene sequences within nuclei as well as confirmation of the methylation
status of the MGMT gene was accomplished by Southern blot analysis using the 3.8
kb EcoRI intron 1 probe described above. As a result of the methylation sensitivity
of EcoRI, the 3.8 kb intron 1 probe recognized two fragments in the EcoRI only
digests of naked DNA (fig.14-16 lanes 5, each panel). The larger, 4.5 kb fragment
was generated from MGMT alleles methylated at the EcoRI site that defines the 3'
end of this probe. The MGMT expressing cell lines had a greater proportion of the
4.5 kb fragments (fig.14-16, lanes 5) indicating a greater degree of methylation at
this site in MGMT+ cells compared to MGMT- cells (lanes 10). Consistent with
the EcoRI digests, the EcoRI/Hpall (fig. 14-16, lanes 4,9) digests also confirm that
the intron 1 region was methylated in the MGMT+ cell lines and relatively
unmethylated in the MGMT- cell lines.

There was no difference in digestion

patterns when the glioma DNA was incubated with the methylation insensitive
enzyme, Mspl (fig.14-16, lanes 3,7). Comparison of the Msp digests of DNA in
nuclei demonstrates that the unmethylated MGMT gene-intron 1 region in MGMTcells is more accessible to Mspl relative to the methylated intron 1 in MGMT
expressing cells, indicated by the presence of three additional probe-recognized
fragments in the DNA from MGMT- cells (fig. 14-16,

~,lanes

1-2) not seen in the

digests of DNA from MGMT+ cells (SF767, lanes 6-7). Incubation of the nuclei
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with 20 U Mspl for 10 min (fig. 14-16, lanes 1,6) yielded the same degree of
digestion as incubation with 150 U Mspl for 2 hrs (lanes 2,7). The differential Msp
accessibility in the intron 1 region is consistent across all 5 cell lines tested (fig. 1416), suggesting that the methylation-related chromatin structure in the body of the
gene may be a relevant component of MGMT transcription. Furthermore, the
positions of the accessible Mspl sites were identical in the nuclei from all three
unrelated MGMT- cell lines tested, and two minimally MGMT+ cell lines (which
are also relatively unmethylated) supporting the idea that methylation and
chromatin structure in the body of the MGMT gene are closely linked, possibly
through MeCps.
As opposed to Mspl, enzymes With non-CpG-containing recognition sites are
only blocked by MeCps if their sites are near a CpG (Antequera, et al., 1989). To
determine if the differences in chromatin structure can be detected with enzymes
that do not contain CpGs in their recognition sequence, the accessibility of Alul to
the MGMT gene within nuclei was tested. Nuclei from 2 MGMT+ and 2 MGMTglioma cell lines were incubated with increasing amounts of Alul, the DNA was
isolated and cleaved with EcoRI and analyzed by Southern blot with the 3.8 kb
intron 1 probe (fig.17-18). Increasing the amount of Alul in the reaction resulted
in increased cleavage primarily in the MGMT- nuclei, but also, to a much lesser
degree in one of the two MGMT+ nuclei (fig.17, SF767).

The extent of Alul

digestion of the MGMT gene was nevertheless significantly greater in MGMTnuclei compared to MGMT+ nuclei, especially in nuclei incubated with 60 U Alul
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Figure 17. Southern blot analysis of Alul accessibility to an MGMT intron 1 region
within intact nuclei from MGMT+ (SF767) and MGMT- (CLA) glioma cells.
Nuclei were incubated with Alul (0 - 60 U for 10 min), the DNA was isolated and
further cleaved with EcoRI. Ten µg of DNA from each digest was analyzed by
Southern blot with the intron 1 probe as described in fig.9.
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Figure 18. Southern blot analysis of Alul accessibility to an MGMT intron 1 region
within intact nuclei from MGMT+ (T98) and MGMT- (A1235) glioma cells. Nuclei
were incubated with Alul (0 - 60 U for 10 min), the DNA was isolated and further
cleaved with EcoRI. Ten µg of DNA from each digest was analyzed by Southern blot
with the MGMT intron 1 probe as described in fig.9.
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Figure 19. Southern blot analysis of DNasel accessibility to an MGMT intron 1
region within intact nuclei from MGMT+ (SF767) and MGMT- (CLA) glioma cells.
Nuclei were incubated with DNasel (0 - 60 U for 10 min), the DNA was isolated and
further cleaved with EcoRI. Ten µg of DNA from each digest was analyzed by
Southern blot with the intron 1 probe as described in fig.9.
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Figure 20. Southern blot analysis of DNasel accessibility to an MGMT intron 1
region within intact nuclei from MGMT+ (T98) and MGMT- (A1235) glioma cells.
Nuclei were incubated with DNasel (0 - 60 U for 10 min), the DNA was isolated and
further cleaved with EcoRI. Ten µg of DNA from each digest was analyzed by
Southern blot with the intron 1 probe as described in fig.9.
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(flg.17,18, compare lanes 4 and 8). Thus, the different chromatin structures of the
MGMT gene within MGMT- and MGMT+ nuclei can be distinguished at CpGcontaining and nonCpG-containing sites.
The chromatin structure of the body of the MGMT gene was also analysed
with a non-sequence specific enzyme, DNAsel, which cleaves DNA in the minor
groove (reviewed in Gross and Garrard, 1988). DNAseI cleaves at nucleosome free
regions (often synonymous with DNAseI hypersensitive sites) when added at low
concentrations to nuclei, and at internucleosomal and intranucleosomal DNA at
much higher concentrations. Nuclei from two MGMT+ and two MGMT- glioma
cell lines were incubated with increasing amounts of DNAseI, after which DNA was
isolated, cleaved with EcoRI and analyzed by Southern blot with the MGMT intron
1 probe (fig.19, 20). DNaseI did not cleave intron 1 at any of the concentrations
shown in these experiments (fig.19,20). The average sized DNA fragment from these
digests, as determined by visual inspection of the agarose gels prior to transfer,
decreased with increasing DNaseI, indicating that much of the genome was cleaved
by DNase, yet the body of the MGMT gene was very resistant to cleavage.
Incubation of the nuclei with 120 U DNase resulted in complete loss of hybridizable
DNA fragments in each cell line.

Thus, there were no detectable differences in the

presence or absence of nucleosomes in the body of the MGMT gene in nuclei from
MGMT+ and MGMT- glioma cell lines.
In summary, MspI and AluI accessibility to the body of the MGMT gene was
greater in nuclei from MGMT- cells relative to MGMT+ cells but MspI
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accessibility was independent of Mspl concentration whereas Alul accessibility
increased with increasing Aloi added. The greater Mspl and Aloi accessibility in
MGMT- nuclei was likely not a result of the absence of nucleosomes in these cells
since no differences in DNasel digestion were seen at any of the DNasel amounts
tested, but may involve MeCps. Binding of MeCps to the methylated MGMT gene
could be relevant in mediating the relationship between methylation and MGMT
expression by maintaining the chromatin structure of the MGMT gene in a manner
that facilitates transcription. These data suggest that alterations in methylation
and chromatin structure in the body of the MGMT gene may be a common feature
associated with loss of MGMT gene expression.

Analysis of Methylation in the MGMT Promoter
The methylation status of the MGMT promoter was determined by linkermediated PCR (LMPCR) analysis of hydrazine treated glioma DNA. As hydrazine,
in the presence of 1.5 M NaCl, reacts preferentially with cytosine but not 5methylcytosine (Ohmori, et al., 1978), methylated cytosines decrease the intensity,
or cause the disappearance of cytosine bands in sequenced DNA. Methylation was
analyzed in two regions of the MGMT promoter that together likely contain all the
basal promoter elements and approximately 60 percent of full promoter activity
(Harris, et al., 1991). Region I includes nucleotides 703-800 and region II, which
includes the transcription start site (nt 955), spans the basal promoter elements
(nucleotides 865-1020) (Harris, et al., 1991). The full nucleotide sequence of these
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Figure 21. Methylation analysis of the MGMT promoter in MGMT+ (SF767),
minimally MGMT+ (Hs683) and MGMT- (CLA) glioma cells by LMPCR. DNA
from the glioma cell lines and plasmid DNA containing a 1.2 kb BamH I/Sst I
fragment of the MGMT promoter was reacted with genomic sequencing chemicals.
All nucleotides (G, guanine, A, adenine, T, thymine, C, cytosine) in the cloned DNA
and guanines and cytosines in the glioma DNA spanning promoter nt 703-800 (A,
region I) and 865-1020 (B, region II) were analyzed by LMPCR. A MGMT
promoter-specific primer (region I, nt 655-675 and region II, nt 805-823), was
annealed to the cleaved DNA and extended (48°C, 15 min) with Sequenase.
Extension products were ligated to a double stranded linker and then amplified by
PCR (5 min, 95°C followed by 18 cycles of 95°C for 1 min, 66°C for 2 min and 76°C
for 3 min with a 5 sec extension of the 76°C step after each cycle and 10 min at
76°C after cycle 18) with the longer (25 mer) linker primer and a nested genespecific primer (for promoter region 1, nt 674-698, for promoter region 2, nt 841861). 32P labelled PCR products were generated through two additional PCR cycles
with a second nested end-labelled primer (for promoter region I, nt 674-702, for
promoter region 2, nt 841-864). Following two cycles of PCR (same parameters as
above except annealing was at 67°C and extension at 77°C), the DNA was extracted,
precipitated, and resuspended in 10 µI. 3 - 5 µl of the sample was electrophoresed
through a 6 % denaturing polyacrylamide gel and then detected by autoradiography
(6-18 h exposure). (•)indicate cytosines within a CpG.
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regions in the cloned promoter as well as the positions of guanines in the glioma
DNA were also confirmed using genomic sequencing chemicals and LMPCR.
Figure 21A and 21B represent autoradiographs of the promoter methylation
analysis in region I and region II, respectively. In both promoter regions, the
relative intensity of most bands representing potentially methylated cytosines
(numbered arrows) decreases, indicating fewer unmethylated cytosines, from SF767
(MGMT+) to Hs683 (minimally MGMT+) and CLA (MGMT-) amplified DNA.
Methylation in these MGMT promoter regions appears uniform within each cell line
and correlates in an inverse, rather than direct, fashion with MGMT expression.
The radioactive signal from 25 of the cytosine bands (of a CpG) was
quantitated directly from the polyacrylamide gels and compared to a nearby non
CpG cytosine to obtain a relative ratio (CpG cytosine/non-CpG cytosine) that
reflects the level of methylation at that site. Determining relative values in this
manner eliminates value variations potentially due to unequal ligation,
amplification, or sample loading. The relative ratios from glioma cell DNAs were
compared to plasmid DNA containing the MGMT promoter (100 percent
unmethylated at all sites)(region I, fig.22A) or to the SF767 cell line DNA (region

II, fig.22B). The results are expressed as percent of MGMT promoter alleles within
each cell line that were unmethylated at a particular site, as the signal measured
was a result of unmethylated cytosines. Methylation appears uniform within each
cell line and graded across the cell lines at eight of ten sites (exceptions are sites

3 and 6) in region I and thirteen of fifteen sites (exceptions are sites 11 and 13) in
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Figure 22. Quantitation of promoter methylation in MGMT+ (SF767), minimal],~
MGMT+ (Hs683) and MGMT- (CLA) glioma cell lines. Promoter methylation w~~
quantitated by measuring radioactive signal from the LMPCR products i~
polyacrylamide gels using a betascope 603 blot analyzer. Methylation values of eac~
CpG were calculated as the ratio of unmethylated cytosine (in a CpG) to ~
neighboring non-CpG cytosine. A, For promoter region I (nt 703-800), methylatio~
from each cell line was expressed relative to the MGMT promoter in plasmid DN~
(100 % unmethylated), and was the average of two independent experimen \
(average difference of 8.6 % between experiments). B, Methylation of CpG's ·~
region II (nt 865-1020) was expressed relative to the SF767 cell line.
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region II, and correlates in an inverse, rather than direct fashion with MGMT
expression. Of the four apparently non-graded sites, three (sites 3,6,11) are still
methylated to a greater extent in the nonexpressing cell lines compared to
expressing cell lines, and one (site 13) is unmethylated in all cell lines. The graded
methylation patterns at the majority of sites across the cell lines implies that there
is a close, inverse relationship between methylation of the promoter and MGMT
expression.

Restriction Enzyme Accessibility to the MGMT Promoter within Nuclei
Because the methylation status of the MGMT promoter was associated with
MGMT expression in a graded, inverse fashion, the possibility that methylation may
influence the chromatin structure of the MGMT promoter, and thus MGMT
transcription, was investigated. The chromatin structure of the MGMT promoter
was analyzed by incubation of nuclei from MGMT expressing and nonexpressing
cells with AvaII or Mspl followed by LMPCR analysis of the DNA.
Figure 23A and 23B show the results of LMPCR analysis of the AvaII
accessibility to promoter region I and region II, respectively. The LMPCR products
of 127 nt (fig.23A) and 140 nt (flg.23B) correspond exactly to the distance between
the labelled LMPCR primers and the Avail sites at nucleotides 773 and 953 of the
MGMT promoter, respectively. The large amount of LMPCR product generated
from DNA of the SF767 nuclei digests and virtual absence from equal amounts of
Hs683 and CLA DNA indicates that the MGMT promoter is much more accessible
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Figure 23. LMPCR analysis of Avail accessibility to the MGMT promoter within
intact nuclei. Nuclei isolated from MGMT+ (SF767), minimally MGMT+ (Hs683)
and MGMT- (CLA) glioma cells were incubated with 16 U Avail for 10 min at 37°C.
DNA was isolated from the nuclei and 5 µg was analyzed by LMPCR as described
in fig. 21, except only one-fifth of the final reaction was analyzed, and
autoradiograph exposures were 2-5 h with intensifying screens. The LMPCR
products of 127 nt (arrow in A, promoter region I) and 140 nt (arrow in B,
promoter region II) are derived from glioma DNA cut at the Avail site at promoter
nt 776 and nt 956, respectively.
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at both Avall sites, and possibly in a more open chromatin conformation, in nuclei
from MGMT+ cells (SF767) relative to minimally MGMT+ (Hs683) and MGMTcells (CLA). The difference in Avall accessibility between the three cell lines was
reproducible in independent experiments.

It is interesting to note that the

differentially accessible Avall site at nucleotide 953 falls in the immediate vicinity
of the transcription start site (955) and several potential Spl binding sites
(Harris,et al., 1991), where chromatin structure might directly influence MGMT
transcription.
Figure 24 represents the LMPCR analysis of MspI accessibility to the MGMT
promoter in nuclei from MGMT+ (SF767), minimally MGMT+ (Hs683) and
MGMT- (CLA) glioma cell lines. Incubation of the nuclei with 20 U MspI (lanes
1- 3) resulted in a much greater cleavage at all promoter MspI sites tested in SF767
nuclei compared to Hs683 and CLA. The difference in MspI accessibility was also
reproducible in independent experiments. Together, all the MspI and Avall sites
are accessible in nuclei from SF767 cells and encompass 372 nt (nt 712-1084,
including an additional MspI site (nt 884) and an Avail site (nt 1084)), a region
of accessible DNA much larger than would be expected if normal nucleosomal
phasing was present (McGhee, et al., 1980). Incubation of nuclei (from the same
isolation) with an excess of MspI (lanes 4-9) resulted in measurable cleavage at all
sites, indicating that the absence of LMPCR products is likely not a result of
contaminants from the nuclei isolation that inhibit MspI digestion or contaminants
that inhibit enzymes used in LMPCR. The MspI sites at 712, 722 and 738 ·(lanes
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Figure 24. LMPCR analysis of Mspl accessibility to the MGMT promoter within
intact nuclei. Nuclei from MGMT+ cells (SF767), minimally MGMT+ cells
(Hs683) and MGMT- cells (CLA) were incubated with either 20 U (lanes 1-3), 200
U (lanes 4-6) or 400 U (lanes 7-9) Mspl, the DNA was isolated and 5 µg was
analyzed by LMPCR. One fifth of each reaction was separated on a 6 % denaturing
polyacrylamide gel and autoradiographed for 2-5 hr in the presence of intensifying
screens.
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1-3) appear to have graded degrees of accessibility across the cell lines that parallel,
in an inverse fashion, the graded promoter methylation, suggesting that methylation
and chromatin structure are closely linked in the MGMT promoter. The restriction
enzyme inaccessible promoter in cells with little or no MGMT expression may also
be inaccessible to endogenous transcription factors. The chromatin structure of the

promoter may therefore determine, in part, the expression state of the MGMT gene.

In Vivo Footprintin& of the MGMT Promoter
Specific in vivo protein-DNA interactions in the MGMT promoter were
examined by linker-mediated PCR of DNA from glioma cells that were exposed to
dimethylsulfate (DMS). As DMS reacts preferentially with the N7 position of
guanines, and subsequent piperidine treatment of the isolated DNA results in
cleavage of the DNA at DMS-methylated guanines (Mattes, et al., 1986), the
LMPCR products generated from this DNA represent the guanines that are
accessible to DMS within intact cells. As DMS is not blocked by nucleosomes or
MeCPs but DNA is protected from DMS by many transcription factors (Pfeifer, et
al., 1989a), the DMS footprinted protein-DNA interactions are qualitatively different
from those assessed by Mspl accessibility.
Figure 25 shows the in vivo footprint analysis of the MGMT promoter, in
MGMT expressing and nonexpressing cells, from nucleotides 700-865 (fig.25A) and
865-1050 (fig.25B), which together include the transcription start site (nt 955) and
likely all the basal promoter elements. There are no detectable footprints in any of
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Figure 25. In vivo footprint analysis of DNA-protein interactions in the MGMT
promoter. Normal human T lymphocytes (lane 1) and two glioma cell lines all with
high levels of MGMT expression (lanes 2-3), one minimally MGMT+ glioma cell
line (lane 4), and three MGMT- glioma cell lines (lanes 5-7) were incubated with
0.1 % DMS (2 min, 37°C). DNA was isolated from the cells, cleaved with piperidine,
and 5 µg analyzed by LMPCR. One half of the reaction was separated on a 6 %
denaturing polyacrylamide gel and autoradiographed for 6-18 hrs. A, Analysis of
promoter nt 700-865; B, analysis of promoter nt 865-1050. Open rectangles are Spl
sites unoccupied in all cells tested. Filled rectangle (I) indicates site that is
footprinted in lanes 1-3 but not in lanes 4-7. Except for the footprint at nt 845-855
(in A, nt sequence given vertically), which is an as yet uncharacterized site, all
footprinted regions are Spl consensus sequences (GGGCGG). -+ in B indicates
transcription start site.
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the cells in the region spanning nucleotide 700-845 (fig.25A), which includes a
putative Spl recognition site (nt 708-713). The guanines at positions 849,851, and
852 however, are protected from DMS in the MGMT+ cells (lanes 1-3) but not in
the minimally MGMT+ (lane 4) and MGMT- cells (lanes 5-7), indicating the
presence of an MGMT expression-associated DNA-protein interaction.

The

protected sequence does not match with any known consensus sequence for
transcription factor binding and may thus represent a novel protein binding site.
In the promoter region spanning nt 865-1050 there are 6 footprints in the MGMT+
cells but none in the minimally MGMT+ or MGMT- cells.

All six of these

footprints correspond to Spl recognition sequences and have 5' hypersensitive
guanines followed by at least five protected guanines, indicating that in MGMT+
cells, these sequences are likely protected by Spl. There are no footprints at the two
overlapping Spl-like sequences spanning nt 875-885, or at the putative CCAAT box
(nt 870-876) in any of the cells tested (fig.258). Normal human T cells, which have
high levels of MGMT expression, have an identical pattern of footprints as the
MGMT+ glioma cell lines, indicating that these DNA-protein interactions are not
confined to cell lines.

Spl appears to be a common feature of and possibly critical

for efficient basal level MGMT transcription. These data strongly suggest that the
chromatin structure of the MGMT promoter determines whether Spl and other
transcription factors can interact with the promoter in vivo, and likely influences
the expression state of the MGMT gene.
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Figure 26. Gel mobility shift analysis of basal Spl binding activity. Ten µg of
protein extract from each cell line were incubated with a double-stranded, . 32Plabeled oligonucleotide containing Spl consensus sequences. The protein-bound and
unbound (free) oligonucleotides were separated by electrophoresis through a 4%
non-denaturing polyacrylamide gel and then detected by autoradiography. Lane 1:
no protein, lane 2; 10 µg HeLa protein extract, lane 3; Hela extract preincubated
with excess cold Spl oligonucleotide (specific competitor), lane 4; HeLa extract
preincubated with excess cold HSE oligonucleotide (nonspecific competitor), lane
5-14; 10 µg protein extract from various cell lines, as noted.
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Analysis of Spl Hindin& Activity
To ensure that the absence of Spl footprints in MGMT- was not simply due
to a lack of Spl protein in these cells, Spl binding activity was measured in protein
extracts from all the glioma cell lines by gel shift analysis. Ten µg of protein
extract from each glioma cell line was incubated with a radiolabelled 22 bp DNA
probe that contains a single Spl binding site. Spl binding activity was detected by
separating the free probe from Spl-bound probe (migrates much slower) by
electrophoresis

through

a

6%

nondenaturing

polyacrylamide

gel

and

autoradiography.
The results of the Spl gel shift analysis are shown in fig. 26. Probe alone (no
protein extract) migrates near the bottom of the gel (lane 1).

Three control

reactions were performed to demonstrate that the protein bound to the Spl probe
is in fact Spl. Incubation of the probe with HeLa cell extract (positive control for
Spl) resulted in a slower migration of the probe through the gel because it is bound
by Spl (a "gel shift," lane 2). Complete elimination of the HeLa cell Spl gel shift
by preincubation of the HeLa extract with an excess of unlabelled Spl probe (self
competition, lane 3) but no such effect by preincubation with an excess with an
unlabelled 22 hp heat shock DNA (nonself competition, lane 4) indicated that the
protein responsible for the gel shift was specific for the Spl probe and likely was
Spl. Gel shifts identical to that seen with HeLa cell extract were easily detectable
in all the glioma cell lines tested (lanes 4-13). All the glioma cell lines therefore
have functional Spl protein, regardless of MGMT expression. These data clearly
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demonstrate that the lack of Spl footprints in vivo in MGMT- cells was not due to
a lack of Spl in these cells and coupled with the data described above, provides
compelling evidence for the involvement of methylation and chromatin structure in
MGMT expression.

CHAPTERV
DISCUSSION

This dissertation was designed to examine the role of cytosine methylation in
the regulation of MGMT gene expression in human glioma cells. The results of
these experiments strongly support the hypothesis that methylation and chromatin
structure are important components of MGMT gene expression in human glioma
cells.

The interpretation, significance, and potential limitations of the results

leading to this conclusion are discussed below.
From the outset it should be acknowledged that regulation of MGMT gene
expression has not been proven to occur at the level of transcription. The protein
coding portions of the MGMT gene are spread over greater than 80 kb (Costello,
et al., 1994) and the entire gene spans more than 170 kb (Nakatsu, et al., 1993), yet
the MGMT mRNA is only 1 kb. The standard explanation for generation of the
mature 1 kb MGMT mRNA involves transcription of all 170 kb of the MGMT gene,
followed by or concurrent with accurate removal (splicing) of 99.4% of the primary
transcript (MGMT hnRNA). In a simplistic sense, the process of generating a
mature MGMT mRNA seems inefficient, and if the RNA polymerase transcribing
the MGMT gene proceeds at a rate similar to other eukaryotic RNA polymerases,
generation of a single MGMT hnRNA or mRNA would take at least 17 minutes. It
102
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is expected that multiple MGMT transcripts initiated in this time period would
increase the number of transcripts generated in a given time period. The high
stability of the MGMT mRNA (half-life > 12 hr (Kroes and Erickson, 1992)), may
also counterbalance the presumably slow MGMT transcription and thereby
maintain higher levels of MGMT expression. Currently, it is unknown whether the
MGMT gene is transcribed in a fashion similar to most other genes. The only
evidence suggesting that the MGMT gene transcription may be atypical is based on
negative data. As opposed to the measurable transcription rate of the majority of
genes, MGMT transcription has not been detected by either nuclear run-on analysis
or PCR amplification of reverse transcribed hnRNA (Russell Pieper, personal
communication; Kroes and Erickson, 1992). It is unclear if these negative results
reflect extremely slow transcription, immediate processing of hnRNA, technical
artifacts, or some combination of these phenomena. MGMT transcription, and thus
transcriptional regulation of MGMT expression, cannot be directly assessed in
either MGMT+ or MGMT- cells.
Several experiments described in this dissertation and elsewhere (Ostrowski,
~.,

1991) provide indirect evidence for transcriptional regulation of MGMT

expression. The absence of MGMT mRNA in three of the glioma cell lines, despite
the presence of a relatively intact MGMT gene suggests that there is a defect in
transcription in these cells. Additionally, the similarity in the rank order of glioma
cell lines according to MGMT mRNA levels and MGMT activity indicates that posttranscriptional regulatory events play little, if any, role in determining the level of

104
MGMT expression (Costello, et al., 1994). The consistently different methylation
status of the MGMT gene, in both the body and promoter, in MGMT+ cells relative
to MGMT- cells is also indirect evidence for transcriptional regulation of MGMT
expression, since transcriptional regulation of gene expression is thought to be
influenced by cytosine methylation. Additionally, the transcriptionally inactive
chromatin and absence of bound transcription factors in the promoter of MGMTglioma cells strongly supports the idea that the MGMT gene is not transcribed in
these cells. Thus, MGMT expression is presumed, but not proven, to be regulated
at the transcriptional level.
Recently, studies of MGMT gene regulation were advanced by the isolation and
characterization of the human MGMT promoter (Harris et al., 1991; Nakatsu, et
al., 1993). The promoter for the MGMT gene has CpG island characteristics and
lacks TATA and CAAT boxes, similar to promoters for many housekeeping genes.
MGMT promoter elements required for basal promoter activity (41% of full activity)
are located between nucleotides 886 and 1157 of the 1157 bp promoter, and contain
the transcription start site (nt 955) and six putative Spl recognition sites (Harris,
et al., 1991).

In human tumor cells transfected with chloramphenicol

acetyltransferase (CAT) constructs containing the MGMT promoter, both MGMT
expressing and nonexpressing cell lines contained the factors necessary for
transcription initiation from the MGMT promoter (Harris, .rt.J!!., 1992), implying
that differences between the transfected and endogenous MGMT promoters such as
methylation status and/or chromatin structure may be important. Changes .in the
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body of the gene may also however, be relevant in MGMT expression as several
studies have shown that the cytosine methylation patterns in MGMT exons are
altered in nonexpressing tumors cells relative to expressing cells (Pieper, fil...Jll.,
1991; Wang, et al., 1992; Cairns-Smith and Karran, 1992). Analysis of the role of
methylation and chromatin structure in transcriptional regulation of MGMT
expression must therefore consider both the body and promoter of the MGMT gene.
In this dissertation, the graded methylation and correlations between
methylation and MGMT expression suggest that in both the promoter and body of
the MGMT gene, methylation may influence the level of MGMT expression. Several
studies have attempted to analyze methylation in the MGMT promoter in cells with
different levels of MGMT expression. One study examining the methylation status
of Hpall sites in the MGMT promoter failed to show a clear association between
promoter methylation and MGMT gene expression, although the close proximity of
the fourteen Hpall sites in the promoter region precluded resolution, by Southern
blot, of the methylation status of these sites (Von Wronski,~., 1992). Analysis
of the methylation status of a single site 70 bp upstream of the transcription start
site demonstrated a negative, but not absolute association between methylation and
MGMT expression, although MGMT promoter activity studies demonstrated that
deletion of 76 bp 5' from, and including this site did not alter promoter strength
(Harris, et al., 1992). Another study examining methylation at Hpall sites in the
MGMT promoter concluded that the promoter was methylated to a greater extent
in MGMT expressing cell lines compared to nonexpressors, although this study also
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used Southern blot analysis and thus did not resolve the relevant HpaII fragments
(Nakatsu, et al., 1993). It is unclear from these studies whether the methylation
status of the MGMT promoter is associated with MGMT expression. Because of
the single nucleotide resolution of polyacrylamide gels and the very sensitive nature
of linker-mediated PCR, the analysis of methylation presented here overcame the
inadequate resolution noted in previous studies. The graded methylation across the
cell lines at 21 of 25 CpGs tested in the MGMT promoter indicates that the
methylation status is uniform within each cell line and that there is a close, inverse
association between overall promoter methylation and MGMT expression (Costello,
et al., 1994). The overall promoter methylation, expressed as the average "percent
unmethylated" of all CpG sites, was similar in region I and II. For region I, the
level was 93 % in SF767, 73 % in Hs683 and 45 % in CLA. In region II, the
promoter was 100% unmethylated in SF767, 74 % unmethylated in Hs683, 58%
unmethylated in CLA. These measurements reflect the average methylation within
a population of MGMT gene alleles. The region II values were expressed relative
to SF767 because the intensity of cytosine bands corresponding to the more 3'
cytosines in the plasmid DNA was somewhat diminished, and thus difficult to
accurately quantitate. As the three 5' most cytosines of CpGs in the plasmid region
II were similar in degree of unmethylation to those in the SF767 cell line however,
and as most sites in SF767 region I were completely unmethylated (given the 8.6 %
average experimental error), it seems reasonable to assume region II cytosines in
SF767 DNA are nearly 100 % unmethylated. It should be noted that in cells that
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do not express the MGMT gene, methylation of the promoter, while less than in
expressing cells, was still only 50 %, rather than 100 % methylation noted in Xlinked inactive genes (Pfeifer, .§_fil., 1990). These data suggest that while inactive
genes on the X chromosome may be 100 % methylated, complete methylation may
not be necessary for processes involved in promoter inactivity.

Using linker-

mediated PCR with hydrazine-reacted DNA, methylated cytosines are identified by
the absence of hydrazine reactivity and hence the disappearance of cytosine bands.
Point mutations that change a cytosine to any other base could also account for the
disappearance of cytosine bands and would be erroneously interpreted as
methylated cytosines. This possibility was completely eliminated in the MGMT
promoter studies by the demonstration that the nucleotide present on the
complementary DNA strand, and base paired with the base in question, was always
guanine (unpublished data). These results suggest that an unmethylated promoter
is required for efficient MGMT expression and that the level of promoter
methylation is closely associated with the level of MGMT gene expression.
In contrast to promoter methylation, the relative contribution of methylation
in the body of genes to the control of gene expression is less understood. However,
the conserved methylation status in the body of many genes implies that these sites
are important, at least in genes in which the body methylation correlates with gene
expression. While methylation in the MGMT promoter correlates inversely with
MGMT expression, the uniform methylation over the body of the MGMT gene and
graded methylation at the intron 1 EcoRI site correlated directly with MGMT
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expression, suggesting that methylation in the body may also influence MGMT
expression in a graded fashion. Although the intron 1 EcoR I site analysis is
consistent with the methylation analysis at Hpall sites in the same region, the
possibility that the inhibition of EcoRI digestion at the internal EcoRI site in
MGMT intron 1 is a result of a point mutation or small deletion that destroys the
EcoRI site cannot be excluded.

This possibility is unlikely, however, as the

probability of this specific mutation occurring independently in all 10 of the
unrelated glioma cell lines tested is exceptionally low. Two limitations of the Hpall
site methylation analysis should also be acknowledged. First, CpGs within Hpall
sites (CCGG) account for only 1/16 of all CpGs in a given region of DNA. The
possibility that the non-Hpall CpGs are not differentially methylated in MGMT+
cells relative to MGMT- cells exists but is highly unlikely, as Hhal sites
(GCGC)(unpublished data) and the EcoRI site in the intron 1 region were also
differentially methylated. Second, for technical reasons, the analysis of Hpall
fragments by Southern blot is limited to DNA fragments greater than 300 bp. If

<300 bp clusters of Hpall sites exist within the analyzed regions of the body of the
MGMT gene, many of these sites, if unmethylated, would not be included in the
methylation analysis. On the other hand, the presence of large probe-recognized
fragments in the DNA of the MGMT+ cells indicates that all Hpall sites within
those fragments are methylated, including any potentially clustered Hpall sites.
Because the body of the MGMT gene is methylated in MGMT expressing normal
human

brain cells

and T lymphocytes, the close association

between
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hypomethylation of the MGMT gene and lack of MGMT expression in glioma cell
lines suggests that maintenance of appropriate levels of methylation in the body of
the gene may be important for MGMT expression. The picture that emerges from
the methylation data is that for efficient MGMT transcription, the MGMT promoter
should be unmethylated and the body of the gene, heavily methylated. Conversely,
increased methylation in the promoter and decreased body methylation are
associated with decreased MGMT expression.

The graded nature of this

relationship suggests that methylation and MGMT gene expression are closely, and
possibly causally, linked.
Several recent studies suggest that in general, methylation and gene
expression are causally linked, possibly in both a direct and inverse fashion. A
study of mutant mice deficient in cytosine methyltransferase (MTase) provided
examples in which preventing normal methylation inhibited gene expression in some
genes and, in other genes, caused activation of normally silent genes (Li, _gt_fil.,
1993). For example, in normal mice, the methylated (in the promoter), paternal
allele of the H19 gene is transcriptionally inactive (Bartolomei et al., 1991), but in
MTase deficient mice, this H19 allele is unmethylated and expressed. In contrast,
2 kb of an intron of the transcriptionally active maternal lgf-2r gene is methylated
in normal mice (Stoger, et al., 1993), but in MTase deficient mice, this intron region
is unmethylated and the maternal Igf-2r gene is not expressed (Li, et al., 1993).
These studies indicate that, at least for the H19 and Igf-2r genes, methylation and
gene expression are causally linked.

These studies also demonstrate that
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methylation can have completely opposite effects on gene expression, apparently
depending on the region of the gene involved. Methylation in the promoter of genes
inhibits gene expression, whereas methylation in introns may facilitate gene
expression. In other genes, a cause and effect relationship between methylation and
gene expression has been tested with the methylation inhibitor 5-azacytidine. For
example, the 5-azacytidine-induced reactivation of the inactive, methylated HPRT
gene occurs only following significant demethylation of the 5' CpG island (Sasaki,
et al., 1992). Several studies have attempted to establish a causal relationship
between MGMT gene methylation and MGMT expression by treating MGMT+ and
MGMT- tumor cells with 5-azacytidine. Treatment of a MGMT+ tumor cell line
with 5-azacytidine decreased methylation in the body of the gene to a level
comparable to a MGMT- cell line and significantly decreased MGMT mRNA levels
(Pieper, .rt_fil., 1991). Additionally, two reports (Mitani, et al., 1989; Ishida and
Takashi, 1988) have demonstrated that treatment of MGMT- human cell lines with
5-azacytidine did not restore MGMT expression. These studies suggest that the
absence of MGMT expression is not solely due to a reversible promoter
hypermethylation, as has been demonstrated in the X-linked HPRT gene, but may
also involve methylation in the body.

In contrast, an induction in MGMT

expression was observed following exposure to 5-azacytidine in two additional
MGMT nonexpressing cell lines, although these studies did not assess methylation
in the body of the gene (von Wronski and Brent, 1994). In sum, these experiments
suggest that 5-azacytidine-induced demethylation can increase or decrease MGMT
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expression, depending on the pre-treatment methylation status and the extent of
induced demethylation of the MGMT gene. The interpretation of these results is
complicated by the fact that 5-azacytidine, in addition to altering gene expression
through demethylation of DNA, can also lead to chromosomal damage and
instability that also potentially alter gene expression. Other more specific methods
of inhibiting methylation, such as inhibition of MTase expression through MTase
antisense oligonucleotides, might be more appropriate in addressing a potentially
causal relationship between methylation and MGMT gene expression. Recent in
vitro studies indicate that methylation of an MGMT promoter-CAT construct with
bacterial CpG methylases reduced CAT gene expression, although it should be noted
that both the MGMT promoter and body of the CAT gene were methylated in these
studies (Harris, et al., 1994). This in vitro study of methylated and unmethylated
MGMT promoter-CAT constructs and the 5-azacytidine studies are inherently
incapable of addressing the relative contribution of methylation in the body and
methylation in the promoter to MGMT gene expression. Although the results of
most of these MGMT gene methylation studies, aside from their limitations, seem
to indicate that there is a cause/effect relationship between methylation and MGMT
gene expression, the events leading to the changes in methylation have not been
identified. Conclusive testing of the potential cause/effect relationship between
methylation and MGMT expression relies first on the identification of the
process(es) leading to aberrant MGMT gene methylation. The expectation is that
methylation changes will precede, or occur concurrent with, MGMT gene
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inactivation, if altered methylation actually causes suppression of MGMT
transcription.
Although a temporal relationship between changes in methylation and MGMT
expression has not been investigated in gliomas or glioma cell lines, deficits in
maintenance of normal methylation during tumorigenesis or tumor progression
could be one mechanism by which the MGMT promoter (CpG island)
hypermethylation and body hypomethylation, and possibly loss of expression, of the
MGMT gene occurs. Clearly, this issue needs to be addressed in human glioma
samples, as the methylation status of the DNA in the glioma cells used in this
dissertation may be influenced by cell culture conditions as well as tumorigenesis.
Examining potential MGMT methylation changes in the well defined stages of
glioma progression could yield information about the temporal relationship between
alterations in methylation and MGMT expression and might eventually be useful
in identifying MGMT deficient, BCNU-sensitive gliomas.
One potential mechanism mediating the relationship between methylation and
MGMT expression involves alterations in chromatin structure. Analysis of Avall
and Mspl accessibility demonstrated that chromatin structure and methylation in
the MGMT promoter are closely linked. The MGMT promoter was much more
accessible to RE in cells with a completely unmethylated promoter compared to cells
with promoters that are, on average, only 74 % unmethylated (Hs683) or 50 %
unmethylated (CLA). The close association between methylation and chromatin
structure was demonstrated by the graded fashion in which accessibility of.at least
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3 Mspl sites correlated with methylation. The accessibility of all sites tested over
372 nt (712-1084) of the basal promoter in the nuclei from SF767 cells (fig. 27)
indicates that this may be a nucleosome-free region, as DNA wrapped in
nucleosomes would be protected from restriction enzyme digestion (Tazi and Bird,
1990). Conversely, the inaccessibility of the promoter at all sites over 372 nt in the
CLA cells (fig. 27) suggests that nucleosomes and/or methylated DNA binding
proteins are present and possibly involved in setting the transcriptionally inactive
state of the promoter in these cells. The results of the chromatin structure analysis
of the MGMT promoter are consistent with the idea that chromatin structure is an
important part of MGMT transcription. Similar to the promoter, methylation and
accessibility in the body of the gene were also closely associated in the expected
fashion. The unmethylated gene in nuclei from three MGMT- cell lines was more
accessible at three Mspl sites, relative to the methylated gene in nuclei from two
MGMT+ cell lines.

The only Mspl accessible sites in MGMT+ nuclei

corresponded exactly to the few unmethylated sites in this region within MGMT+
nuclei. These data demonstrate that methylation and chromatin structure in the
body of the MGMT gene are intimately associated and suggest that MeCPs may be
mediating this association. These differences in accessibility can also be detected
with Alul, which cleaves DNA at non-CpG containing sites. This suggests that
either the Alul sites are sufficiently close to a CpG and are blocked by a nearby
MeCP, or that some other component of the chromatin structure, such as histones,
is present in MGMT+ cells but is absent or displaced from the MGMT gene in
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Figure 27. Summary diagram of in vivo footprints in, and restriction enzyme
accessibility to the MGMT promoter in MGMT+ (SF767) and MGMT- (CLA)
glioma cells. Filled rectangle (I) indicates footprinted Spl site, open rectangle
indicates unoccupied Spl sites. Filled oval denotes footprinted site of undefined
nature and the open oval is the same site unoccupied. .a. indicates restriction
enzyme accessible site; M, Mspl, A, Avail.
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MGMT- cells. The latter possibility in unlikely though, as DNAsel, which readily
cleaves histone-free DNA but not DNA within nucleosomes, does not cleave the
MGMT gene in any of the nuclei. The

~ssociation

between decreased Mspl/Alul

accessibility and active transcription in these cells however, is surprising, as
transcription is generally associated with a more open, accessible chromatin
conformation. A mechanism by which the more "closed" chromatin conformation
in the body of genes might facilitate transcription has not been defined. The
identical nature of the closed conformation in all MGMT+ cell lines tested, and the
absence from all three MGMT- cell lines however, suggests that there is some
functional importance associated with the chromatin structure in the body of the
MGMT gene. Additionally, the fact that more than 30 unrelated cell lines are
differentially methylated in the body of the gene (Pieper, .rtJtl., 1991; Wang, .rtJtl.,
1992) in the same manner described here, suggests that disruption of the
methylation-related chromatin structure may be a common event contributing to
loss of MGMT expression. The results of the chromatin structure analysis of the
body and promoter are consistent with the idea that chromatin structure is an
important part of MGMT transcription. The chromatin structure in the promoter
of the gene may influence MGMT expression by allowing or excluding transcription
factor access to relevant promoter sequences.
The methylation-related chromatin structure in the MGMT promoter is closely
associated with in vivo transcription factor occupancy. In addition to the general

association between accessible chromatin and transcription factor occupancy,
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several footprints that are positioned closely to restriction enzyme accessible sites
reveal specific examples of this association. For example, the protected guanine at
nt 852 was only 3 nt away from an accessible Mspl site and the presumably Spl
protected guanine at 965 was only 7 nt away from an accessible Avail site (fig. 27).
Spl is the only detectable factor interacting with the minimal promoter elements (nt
886-955), indicating that Spl may be sufficient, in conjunction with protein-protein
interactions, for basal level MGMT transcription. DNA-protein interactions were
not detected on the opposite strand (nontranscribed strand) in the basal promoter
(Russell Pieper, personal communication), which includes an imperfect Spl
consensus sequence.

The possibility that other transcription factor-promoter

interactions relevant to basal expression occur at non-guanine residues cannot be
excluded, although there are no other known transcription factor sites within the
minimal promoter elements. In fact, no other DNA-protein interactions can be
detected at guanines on either strand of the entire 1157 bp MGMT promoter
(Russell Pieper, personal communication). It is not unexpected that there are no
discernable footprints in the promoter of Hs683 cells, which express very low levels
of MGMT, because the Hs683 promoter is inaccessible, relative to SF767. It is
probable that Spl does nevertheless interact with the Hs683 promoter, but only too
infrequently, as dictated by accessibility, to detect with DMS footprinting. The
footprint at nt 845-852, while not within the proposed minimal promoter, is
associated with MGMT transcription, as it is present in the expressing cell lines

and T cells and absent from all three non-expressing glioma cell lines. This
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presumably expression-related protein-promoter interaction is of note for three
reasons. First, previous in vitro studies showed that addition of promoter nt 807883, which includes the footprinted site, to the minimal promoter did not increase
MGMT promoter-driven CAT expression (Harris,fil.Jll., 1991), suggesting that these
sequences are inconsequential to MGMT promoter activity. As the effect of deletion
of only these sequences from the full promoter was not tested, it remains possible
that these sequences are important for promoter activity, but that their contribution
is influenced by interactions with other promoter regions. Such interactions have
been noted for synergistically functioning, yet distant Spl sites

(Su,~.,

1991).

Second, the DNA-protein interaction is novel as it involves nucleotides that do not
correspond to any known transcription factor binding site. Although the footprinted
sequence has minimal homology to an Spl site (7 of 10 nt), and several sequences
that deviate from the canonical Spl site can bind Spl (Brown, .§.Jtl., 1992), the
pattern of the protected sequence is distinct from the canonical Spl protection, as
seen at the other 6 footprints in the MGMT promoter. Third, in contrast to the
single strand Spl footprints, the novel footprint is present on both DNA strands
(Russell Pieper, personal communication). The data indicate that the protein
interacting with promoter nucleotides 845-852 is not Spl and suggest that it may
be a novel transcription factor, or a known transcription factor interacting with a
novel binding site. Three additional sequences previously described as potential
Spl sites based on sequence analysis (12), are not protected in any of the cells
tested, suggesting that these sites do not function as Spl sites in vivo. Since these
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sites have only marginal similarity to Spl sites (7of10 nt) it is possible that these
sequences are incapable of binding Spl. These in vivo results further support the
idea that methylation-related differences in chromatin structure of the MGMT
promoter determine whether Spl, and possibly other factors necessary for MGMT
expression, can interact with the MGMT promoter.
Given some latitude for speculation, the correlative data presented in this
dissertation can be incorporated into a model of MGMT transcription. The MGMT
promoter, like other CpG island-containing promoters, must be maintained in the
unmethylated state for efficient transcription initiation.

Maintenance of the

unmethylated state could occur through binding of the 6 Spl molecules per
promoter. If these sites are occupied by Spl shortly after DNA replication, Spl may
block access to the basal promoter by cytosine MTase, and thus, maintain the
unmethylated state. This part of the model is compatible with the fact that several
CpGs 5' to the Spl sites are not protected by proteins, and are also methylated in
MGMT+ and MGMT- cells (Qian, ..tl__fil., 1994). Spl may therefore serve two
purposes in MGMT expression. Spl may help maintain the unmethylated state of
the basal promoter and likely also facilitates the assembly of the transcription
complex. There is no obvious spatial pattern to the occupied Spl sites, although
all 6 Spl molecules contact guanines which are likely on the same face of the double
helix. This arrangement may be relevant to the known transcription activating
function of Spl. Spl is not bound to the methylated basal promoter possibly
because MeCPs (or other chromatin structure proteins) bind these sites before or
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more efficiently than Spl. Alternatively, the methylated promoter, similar to other
methylated sequences, may be replicated at a later stage when much of the Spl has
been committed to other gene regulatory sequences.

According to these

suppositions, the affinity of Spl for each site in the unmethylated MGMT promoter
would be much higher than the affinity of MeCPs (if MeCPs bind unmethylated
DNA at all). As methylation increases to 25% (as in Hs683) the relative affinities
may approximate each other and transcription may be initiated much less
frequently, only when Spl can occupy a critical number of sites. These less frequent
Spl-promoter interactions would probably not be detectable by standard DMS
footprinting. Between 25% and 50% basal promoter methylation, the promoter
affinity shifts in favor of MeCP, resulting in exclusion of Spl and suppression of
transcription initiation. Analysis of the Sp 1 footprints at all stages of the cell cycle
in synchronized cells might provide indirect evidence for thi.s scheme. Any model
of MGMT transcription must also incorporate the relative efficiency of transcription
elongation, as the methylation-related chromatin structure in the body of the
MGMT gene is different in MGMT+ compared to minimally MGMT+ cells (or
MGMT+ cells treated with 5-azacytidine) and might facilitate or impede the
transcription elongation complex. Since the changes in chromatin structure in the
body of the gene are clearly related to methylation, MeCPs are possible candidates
for mediating this relationship. Binding of MeCPs across the body of the gene
could establish an efficiently transcribed DNA conformation by preventing binding
of other proteins, such as histone Hl, that are known to contribute to

120
transcriptionally inactive chromatin. Binding of MeCPs in the body of the gene
would likely be weak because the CpG density is low relative to CpG islands. Thus,
the MeCPs in the body of the gene could facilitate transcription by preventing the
binding ofhistone Hl-like proteins, while being easily displaced by RNA polymerase
II during elongation. Alternatively, MeCPs may be bound to the body of the gene
at specific sites to properly position the gene sequences within a transcriptionally
active region of the nucleus. MeCPs might accomplish this through maintaining
appropriate DNA attachment to the nuclear matrix, or orienting the exons near
each other on adjacent chromatin loops to facilitate accurate and immediate
splicing events. The conserved chromatin structure in the MGMT+ cells and
disrupted chromatin structure at the same, specific sites in each of the minimally
MGMT+ and MGMT- cells supports the idea that chromatin structure in the body
of the gene is relevant to transcription.
The findings that the promoter in the MGMT expressing cells is unmethylated,
accessible and occupied by transcription factors, suggest that MGMT expression is
dependent on these factors. Since MGMT expression is a major determinant in
sensitivity versus resistance to BCNU (Day, et al., 1980), methylation, chromatin
structure and transcription factor occupancy of the promoter could be viewed as
critical elements of the molecular mechanisms that determine the chemosensitivity
of these glioma cells. In support of this, MGMT expressing SF767 cells are much
more resistant to BCNU compared to the non-expressing CLA cells (Sariban, et al.,
1987; Mitchell, et al., 1992). The fact that gliomas of oligodendrocytic origin are
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especially sensitive to nitrosourea-based chemotherapy (MacDonald, ~., 1990)
implies that MGMT gene inactivation may be a frequent event, possibly mediated
by changes in methylation, chromatin structure and transcription factor access, in
these tumors. Consistent with this speculation, a recent study has demonstrated
that oligodendroglioma tumor samples are in fact very low in MGMT activity (Nutt,
et al., 1994). Furthermore, as inhibition of MGMT in tumor cells is a current goal
of BCNU-based chemotherapy, the "open" chromatin conformation of the promoter
in MGMT-expressing (and hence BCNU resistant) glioma cells may be a good
target for inhibition of MGMT expression, possibly through triple helix formation.
To be of therapeutic value, inhibition of MGMT through triple helix forming
oligonucleotides should be tumor specific. Since the MGMT promoter in normal
and BCNU-resistant tumor cells is likely identical, the tumor specificity of MGMT
inhibitors relies on tumor-specific delivery of these molecules. Direct delivery of
BCNU to glioma cells has been accomplished by implanting BCNU-saturated
anhydrous wafers directly into the tumor area following surgery. The results from
phase I clinical trials of this therapy in glioma patients indicates that the BCNUinduced systemic side-effects are significantly reduced or absent (Brem, et al., 1991).
Incorporation of potential inhibitors of MGMT expression, such as triple helix
forming oligonucleotides, into the slow-release wafers might then also provide
tumor-specificity of MGMT inhibition and hence sensitization to BCNU. Obviously,
testing triple helix-forming oligonucleotides in MGMT inhibition is the next
preliminary step towards achieving these therapeutic goals.
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